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 ABSTRACT 
Introduction: South Africa has embarked on a massive roll out of ARVs to more than 1.4 
million people living with HIV/AIDS. Provision of ARVs to people living with HIV/AIDS 
encounters many challenges associated with adherence. Properly taken ARVs have been shown 
to reduce viral loads to undetectable levels and increase the CD4 count. This in turn leads to a 
drop in opportunistic infections and better health outcomes but the requirements for adherence 
are high. Several patient-related factors have been reported to affect adherence rates. Non-
adherence on the other hand has been reported to lead to the development of drug resistant 
strains of HIV. It recognised that the resistance to ARVs can quickly lead to build up of highly 
resistant strains in the blood due to one week of missed medication.  
 
Aims and objectives: This study set out to identify factors which affect adherence to HAART 
among adults on HAART in two health facilities in Gauteng province in 2006.The main 
objectives were to assess the patient adherence using viral load response and self-report data. 
Secondly, the study was to determine factors that facilitate adherence and finally barriers to 
adherence at the two sites. 
 
Materials and methods: A cross sectional study was done at the two ARV facilities in Gauteng 
from July to November 2006. Two physiological methods -CD4 counts and plasma viral load, 
and one subjective-3 day recall self- report methods were used to asses adherence. Exit 
interviews and record reviews were done to collect data. Virologic outcome was the  preferred 
surrogate marker for adherence. Univariate and bivariate analyses were done to determine 
measures of association. Measures of association (Chi square) at a 95% significance level for 
factors affecting adherence were then determined and results obtained. 
 
Results: The mean age was 36.9 years (range 18-70 years) and 73.5% were women. Self-report 
data (n=343) indicated 98.4% in the higher adherence category (taken 100% of their doses). Viral 
load data (n=343) showed that 88.8% were in the adherence lower category (<400 RNA copies). 
Viral load outcome (“adherence”) was significantly associated with the length on treatment 
(p<0.05) and patients who had been on treatment for 12-24 months had lower viral load than 
those who had been treatment for a shorter time (<12 months) or longer (>24months). 
However, gender (p=1.000), age (p=0.223), level of education (p=0.697) and access to social 
grants (p=0.057) were not associated with “adherence”. Socio-economic status was significantly 
associated with viral load outcome (p<0.01) as well as cost (n=185; p<0.05). Individuals who 
incurred the highest costs (>R25) were the least likely to adhere followed by those facing average 
costs (R15-25) compared to the reference group (< R15).  
 
Conclusion: Adherence rates of 88.8% suggest that respondents from both facilities can 
optimally adhere to their medication when they have been on ARVs for longer than a year. 
These are minimum adherence rates. There were factors that still hinder adherence at both the 
individual patient level. There is still a need for more targeted interventions especially towards 
men who were noted to have a relatively low uptake of HAART within the two sites.  
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CHAPTER ONE: BACKGROUND 
1.1 INTRODUCTION 
In 1996 HAART was launched as one of the latest therapies on the frontier to combat 
HIV/AIDS. Nine years later the government of South Africa launched a roll out programme in the 
public health sector health facilities to more than one million people in need of treatment. This also 
initiated challenges associated with non-adherence.  
Adherence is now recognised as key to effective antiretroviral therapy if viral loads are to be 
brought down to manageable levels and resistance avoided. Benefits which accrue from such therapy 
therefore need to be maximized in resource constrained environments. This study therefore set out to 
explore and document the factors that are associated with adherence at two public sector health facilities. 
Ethical permission was sought from the Wits University and permission sought and obtained from the 
provincial and facility managers to carry out the study. Requirements for anonymity and confidentiality 
were strictly adhered to throughout the study. The study population was mainly males and female patients 
registered at the two health care facilities on HAART for longer than 3 months. 
The study was based on an evidence based health care model for management of the chronically 
sick(CCM).This study thus focuses on one of the elements of the CCM ,mainly the patient side factors 
and how they influence adherence outcomes. The main factors that were investigated include the 
following: Socio-demographic variables, health literacy (health knowledge), medication adherence 
support, HIV status disclosure and their association to viral load outcomes. 
A cross sectional study was done utilizing exit interviews to collect data for the study. There were 
355 interviews of which 343 were eligible for data analysis. More than 70% were females and the 
population had a mean age of 36.9 years. Only 1% reported being on medical aid whilst half were 
receiving a social support grant. More than 99% reported not missing their medication but on the other 
hand the viral load outcome indicted that only 88% had lowered viral load. Adherence rates suggest that 
if optimally supported, patients’ adherence well in comparison to those elsewhere. The results further 
indicated that there were factors that still hinder adherence at the individual patient level in addition to the 
wider health system level.  
1.2 THE HIV/AIDS TIME LINE 
According to the 2006 report on the global AIDS epidemic of the UNAIDS, it has marked more 
than 25 years since the first AIDS cases were reported.  
From the same report a summary timeline of the development of key events is outlined below: 
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In 1981 the first cases of unusual immune deficiency are identified among gay me in the USA and 
a new deadly disease noticed (UNAIDS, 2006). 
In 1982, the Acquired immune deficiency Syndrome (AIDS) was identified for the first time. 
AIDS is defined for the first time. The human immunodeficiency virus (HIV) was identified for the first 
time.  
1983- A heterosexual epidemic is revealed in Africa. The first AIDS cases were reported in South 
Africa in 1983. At that time the numbers were small, affecting mostly white gay men, haemophiliacs and 
some intravenous drug users 
1985-The first HIV antibody test becomes available. While there was little focus on HIV/AIDS 
in South Africa in general, the AIDS Advisory Group was appointed at that time. 
1989-The WHO launches the Global programme on AIDS. The first therapy for AIDS; AZT is 
approved for use in the USA. 
1990-The first antenatal surveys to test for HIV rates in pregnant women were carried out in 
South Africa. 0.8% of women were found to be HIV positive. It was estimated that there were between 
74 000 and 120 000 people in South Africa living with HIV.  Since this time, antenatal surveys have been 
carried out annually. 
1991-1993- HIV prevalence in young pregnant women in Uganda and in young men in Thailand 
begins to decrease, the first major down turns  in the epidemic in developing countries. In South Africa 
the first governmental response to AIDS came when President Nelson Mandela addressed the newly 
formed National AIDS Convention of South Africa (NACOSA). Although there was little action from 
the government in the following few years, the purpose of NACOSA was to begin developing a national 
strategy to cope with AIDS. 
1994-Scientists develop the first treatment regimen to reduce mother to child transmission of 
HIV.  
1996- Highly Active Antiretroviral Treatment is launched. 
1997- Brazil becomes the first developing country to provide antiretroviral therapy through its 
public health system. By 1998 the prevalence rate in South Africa had climbed to 22.8%.  The pressure 
group the Treatment Action Campaign (TAC) was launched under the leadership of Zackie Achmat.  The 
TAC has played a major role in advocating for the rights of people living with HIV/AIDS and in 
demanding a national treatment plan for those who are infected.  
2001-The UN General Assembly special session on HIV/AIDS , the Global fund to fight AIDS, 
Tuberculosis and malaria is launched. 
2003-WHO and UNAIDS launch the ‘3X5’ initiative with the goal of reaching 3 million people 
in the developing world with antiretroviral treatment by 2005. In August of 2003 the Health Department 
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was directed to develop a detailed plan for the roll out of antiretroviral (ARV) drugs to those who were 
living with HIV/Aids.   
2003-After much delay the government finally committed to providing free treatment to 53,000 
patients by March in South Africa. The program began in Gauteng province, where five major hospitals 
began treatment.  It is estimated that there are currently 110 000 patients in the public sector and 80 000 
in the private sector who are currently receiving treatment at 192 facilities around the country.   
1.3 OVERVIEW OF THE GLOBAL AIDS EPIDEMIC 
To date around 38.6 million people have been infected with HIV (Fig1-1). The vast majority of 
the 38.6 million people living with HIV in 2005 were unaware of their status (UNAIDS, 2006).In that 
period deaths attributable to AIDS  have risen from almost none in 1980 to more than 25 million men 
and women, orphaning millions of children, exacerbating poverty and hunger and in some countries even 
reversing human development altogether. From the UNAIDS report of 2006, the global HIV incidence 
rate (the annual number of new HIV infections in a population of previously uninfected persons) is 
believed to have peaked in the late 1990s and to have stabilised subsequently. The numbers of people 
living with HIV have continued to rise, due to population growth and more recently, the life prolonging 
effects of antiretroviral therapy. 
Figure 1-1: Global HIV infection in 2005. 
 
 
An estimated 38 million people world wide were living with HIV in 2005(Fig 1-2). An estimated 
4.1 million became newly infected with HIV and further 2.8 million lost their lives to AIDS.  
Globally, there were an estimated 17.3 million women living with HIV in 2005 – three quarters 
(or 13.2 million) were living in sub-Saharan Africa. Around 59% of all adults living with HIV in sub-
Saharan Africa were women (UNAIDS, 2006).  
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Figure 1-2: Statistics and features of the HIV/AIDS epidemic 
 
Source: global report on the HIV/AIDS epidemic, UNAIDS.2006 
1.4 HIV/AIDS IN AFRICA 
Sub-Saharan Africa is the region of the world that is most affected by HIV/AIDS (Fig1-2). An 
estimated 25.8 million people in the region were living with HIV and approximately 3.2 million new 
infections occurred in 2005. The rates of infection are not uniform throughout Africa.  West Africa is 
generally less affected with increasing rates of infection in South Africa (Fig 1-3). 
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    Figure 1-3: Adults (aged 15-49 years) HIV/AIDS prevalence in sub-Saharan Africa 
 
  In 2005, the region was home to 2 million children under 15 years of age living with HIV. 
Almost 90% of the total numbers of children living with HIV are in sub-Saharan Africa and fewer than 
one in ten of those children are being reached by basic support services.  
 An estimated 12 million children under the age of 17 (just under 10% of children) living in sub-
Saharan Africa have lost one or both parents to AIDS. In 2005, an estimated 2.7 million people in the 
region became newly infected with HIV and 2 million adults and children died of AIDS. Around 72%  
(4.7 million) of all people in need of antiretroviral therapy live in sub-Saharan Africa. In 2005 around one 
in six people in need of treatment in the region were receiving it. 
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There are varying statistics with respect to HIV/AIDS prevalence that were reported in the 
UNAIDS (2005) report. In East Africa HIV prevalence was reported to either have decreased or 
remained stable from the past years. There were 1.3 million people living with HIV in Kenya in 2005. 
Interestingly, the UNAIDS report indicates that the national HIV prevalence fell from 10% in the late 90s 
to stabilise around 6% in 2005. This was attributed to rising condom use, women delaying sexual debut 
and people reducing the number of sexual partners based on the various surveys that UNAIDS quoted. 
Uganda has seen a steep decline from more than 35% in the mid 80s to late 90s to stabilise around 6.7% 
with more than 1 million people living with the virus in 2005.In Tanzania a prevalence of 6.5% in adults 
was noted in 2005 with about 1.4 million people. The epidemic although appearing to have stabilised, is 
noted to have increased markedly in the older people reaching 13% among women aged 30-34%. In 
Somalia, although national HIV prevalence is low (0.9% of adults), knowledge of HIV transmission is 
poor and condom use uncommon – one study showed that 17 out of 20 men and 19 out of 20 women 
aged 15-24 years old had never used a condom. 
West Africa has generally been less affected by HIV/AIDS compared to the rest of sub-Saharan 
Africa based on the prevalence rates. At 7.1% Côte d’Ivoire has the highest national HIV prevalence in 
West Africa. Available data show that the epidemic appears to have stayed relatively stable for almost a 
decade and significant declines in HIV prevalence are being seen in pregnant women. Nigeria has the 
third-largest number of people living with HIV in the world at 2.9 million. Infection levels vary across 
this large country – from 1.3% in the south west to 4.9% in northern and central areas. Sex work is a 
driving factor in Ghana’s epidemic, where adult HIV prevalence is estimated at 2.3%. Infection levels 
have been rising among antenatal attendees and reached just under 4% in 2005. In the Democratic 
Republic of the Congo an estimated 1 million people were living with HIV in 2005. Adult HIV 
prevalence was estimated at 3.2%, but HIV prevalence as high as 7% was found in pregnant women in 
Lubumbashi. 
1.4.1 SOUTHERN AFRICA  
 
In Southern Africa, HIV prevalence levels are exceptionally high (except for Angola at 3.7%). 
Southern Africa has nine of the ten highest HIV/Aids prevalence rates in the world and more than 3, 3-
million orphans due to the virus. This combination is straining government budgets for health care and 
social services, food security, education, communities and extended families (Mail and Guardian, 13th 
December, 2006). However, in Zimbabwe, where 1.7 million people are living with HIV, data have 
shown a decline in HIV prevalence which is currently estimated at 20.1%, down from 22.1% in 2003. 
This decline has two possible causes; studies have shown both a substantial increase in condom use since 
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the early 1990’s and that more young people have been delaying their sexual debut and reducing the 
number of casual sexual partners; however, a significant factor in the decline is attributed to high-
mortality rates.  
There were no signs of a decline in other parts of southern Africa, at the end of 2005.Botswana’s 
national HIV prevalence stood at 24.1%, Namibia’s was at 19.6% and Swaziland’s at 33.4%. In Swaziland, 
HIV prevalence among pregnant women attending antenatal clinics rose from 4% in 1992 to 43% in 
2004. 
South Africa’s epidemic is now one of the worst in the world with an estimated 5.5 million 
people (18.8% of adults) living with HIV in 2005. Almost one in three pregnant women attending public 
antenatal clinics were living with HIV in 2004 and trends show a gradual increase in HIV prevalence. 
Around 600,000 are sick with AIDS i.e. 11% of those infected by HIV. There has been significant scale-
up on the treatment front – around 190,000 people were receiving therapy by the end of 2005 – however 
this still  only represents less than 20% of those in need. 
According to ASSA (2003) projections and estimates, the prevalence of HIV/AIDS in the 
country and most provinces is reaching a plateau with KwaZulu-Natal having the highest (40% antenatal 
prevalence), the Western Cape the lowest (estimated antenatal plateau of 15.5%). The Northern 
Cape(19.9%) and Limpopo(19.6%) were slightly higher than the Western Cape while the other provinces 
were are expected to either level off or peak at an antenatal prevalence of between 30-35% among which 
was Gauteng Province (35.8%). 
Some key indicators from the ASSA (2003) projections include the impact and death indicators 
of the HIV/AIDS epidemic across South Africa. The impact of the epidemic has been felt all over the 
country with the greatest impact in KwaZulu-Natal and the least affected being the Western Cape. Some 
key findings from the report include the following: Kwa Zulu-Natal accounted for 28.7% of all infections, 
while Gauteng accounts for 26.2%. The Western Cape was providing HAART to about 8%, Gauteng to 
about 5% while the Eastern Cape was reaching only about 3%. Kwa Zulu-Natal accounted for nearly a 
third of all orphans with Gauteng the next highest at 18%. With a population of 7.54 million people in 
1996, Gauteng’s population had risen to an estimated 9.68 million people in 2006 according to ASSA 
(2003) estimates. The total number of HIV positive people by 1997 was estimated to be 279,208 infected 
people and currently is estimated to be more than 1.4 million people. For South Africa as a whole, the 
total cumulative AIDS deaths for South Africa were estimated at 6,074 in 1996 compared to 2006 
(estimated at 437,762).The total AIDS orphans were estimated at 4,465 of the total number of 63,264 in 
1996 while in 2006 they were estimated at 203,287 of the total orphan population of 277,109 with a rise 
of 59,000 orphans from the previous year. 
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The AIDS epidemic, which is estimated to have resulted in the death of more than 
688,000(SAHR,2000) people in South Africa by mid 2002, has caused profound negative social, economic 
and individual effects and has placed a particularly heavy toll on existing health care systems, particularly 
those already facing severe resource constraints. Businesses, and consequently South Africa’s economy, 
incur huge financial losses each year to HIV/AIDS. A study commissioned by AIC Insurance last year 
showed that South Africa lost about R12-billion a year because of workplace absenteeism, of which 
between R1,8-billion and R2,2-billion could be attributed to HIV/Aids, with close to one in five South 
Africans between the ages of 20 and 64 are infected with HIV-a large part of South Africa’s workforce 
(The Mail and Guardian,13th December,2006). 
1.4 STATEMENT OF THE PROBLEM 
South Africa’s commitment to roll out anti-retroviral therapy (ART) to over 1.4 million people in 
South Africa by 2008 has initiated challenges associated with non-adherence and related interventions to 
promote lifelong adherence (Hanson et al, 2003).Anti-retroviral (ARV) provision to people living with 
HIV/AIDS (PLWHA) encounters challenges associated with adherence. Adherence is key to the 
effectiveness of ARVs in bringing the viral loads of PLWHA to manageable levels (Carpenter et al, 1997). 
Poor adherence leads to the development of resistant strains of the virus leaving drug naïve patients with 
few effective treatment options given the length of time it takes to develop and test a single drug and 
have it approved for human use.  
This massive roll out programme will have several negative impacts on the health system itself 
especially the service providers, health facilities and service provision within the health system that is 
stretched to the outmost limits. Although effective provision of ARVs will reduce the numbers of critical 
ill AIDS patients in hospitals, the use of the health services for chronic out-patient care will increase. This 
may impact on the health care seeker especially regarding access and referral to the nearest facilities. With 
an ever increasing demand for more from the health sector, it is therefore important to ensure that 
patients on HAART adhere to the anti-retroviral therapy in order to maximise the benefits that accrue 
thereof in such a resource constrained environment. 
There is very little published information in South Africa about factors associated with non-
adherence let alone those that facilitate adherence to HIV medication in the public health sector from a 
patient’s perspective. There is therefore need to gain a better understanding of these factors that facilitate 
adherence and barriers to adherence in order to design better implementation strategies and ensure that 
resistance is prevented or minimised in the long term. 
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1.5 RATIONALE FOR THE STUDY 
In the literature, adherence to antiretroviral therapy (ART) still dominates debates as one of the 
challenges facing continued treatment of HIV positive patients and health service delivery (Chesney, 
2000; Fogarty et al, 2002; Simoni, 2003, Orrell et al, 2003). Properly taken ARVs have been shown to 
reduce viral loads, but the requirements for adherence are high, with most studies suggesting that it has to 
be higher than 90% to avoid the risk of resistance (Singh et al, 1999; WHO, 2005). There are many 
factors that have been reported to negatively affect adherence leading to non adherence. These factors 
were broadly categorised in a review by Chesney as those related to the patients themselves, medication 
and the system of care. (Chesney,2000).Among the problems noted in the various studies concerned with 
non-adherence by patients have been: failure to fill prescriptions at the clinic due to travel away from 
home, go to appointments and take medication outside the home which can be attributed to the fear of 
disclosing one’s status ,forgetfulness or being too busy, changes in daily routine of the patient, the side 
effects of the medication, depression or illness and lack of interest or taking drug 
holidays(Chesney,2000;Golin et al; 2002; WHO, 2005).  
 This research investigated the barriers associated with adherence on the public health HAART 
pilot programme. It is hoped that the results of this research will inform operational research and 
programme managers enhance better patient management in order to lead to better adherence and 
enhanced quality of care. The results will further be disseminated to policy makers in order to inform and 
contribute to the decision-making process about chronic care of PLWHA in Gauteng Province. 
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CHAPTER TWO: LITERATURE REVIEW 
2.1 THE CHRONIC CARE MODEL (CCM) 
The current study will draw on an evidence based model framework, the Chronic Care Model 
(CCM), designed to guide quality improvement in health care activities first described and developed by 
(Wagner et al,2001). He suggests that in order to ensure improvement in the provision of chronic care, 
there needs to be a focus on several crucial components. These are broadly divided into first, the provider 
oriented components and secondly the patient oriented interventions all interacting to ensure productive 
interactions between the patient and provider that will eventually lead to effective and beneficial chronic 
disease management (in this case HAART).  
 The health care system is depicted as a part of a larger community with the ARV clinic as part of the 
health care organisation (Fig 2-1) .The framework provides a guide linking the health care system with the 
patients on HAART. Interactions are further described  as productive between the providers and the 
patient with the ultimate goal of ensuring that patients are informed, activated and able to cope with 
challenges of living with and treating the chronic illness (Wagner et al, 2001: page 68).  
 The CCM model stresses interventions that encourage people to acquire self management skills that 
are essential to chronic care. This in effort to improve health care delivery systems traditionally designed 
for acute illness, towards chronic illness. A common set of challenges is presented by chronic illnesses to 
the sufferers and their families-dealing with symptoms, disability, emotional impacts, complex medication 
regimens, difficult lifestyles adjustments and obtaining helpful medical care. Persons in contact with the 
heal care system should be empowered to ensure that they are informed, confident and have the skills 
necessary to manage their condition and thus ensure that they can productively take part in their health 
care (Wagner et al, 2001: page 64). 
This forms a shift in focus from the traditional health care system that sought to treat illnesses as 
they presented within the health care system to meeting the needs of the chronically ill since they are 
more likely to be part of the health care setting for a long time. As Wagner, 2003 summarises; “The CCM 
shifts focus from the historical didactic education of the patient to a more pragmatic form of 
encouragement and support for the more effective self-management. It also emphasises the patients’ 
crucial role in maintaining health and function, the importance of setting goals, establishing action plans, 
identifying barriers, and solving problems to overcome barriers.” 
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Figure 2-1: The CCM: A performance framework 
 
Source: adapted from Schneider et al, 2007 
2.2 DEFINING ADHERENCE  
The definitions of adherence are many and have changed to suit the particular context within 
which they are applied. Some examples include the following: 
Adherence is defined by most dictionaries as “to stick, to remain loyal, or to have fidelity”. Since 
adherence to complex medical regimens requires an active interaction between patients, disease, 
treatment, medical care and outcome it was felt that terminology that implies a more active role for the 
patient was preferable, rather than the phrase “compliance” (Garcia et al, 2003).  
Adherence, “the extent to which a person’s behaviour-taking medication, following a diet, and/or 
executing lifestyle changes-corresponds to with agreed recommendations from a health provider” 
(WHO, 2002: page 1), is a crucial element for the implementation of the HIV treatment scale-up 
initiative.  
Therefore to achieve the aims of this study, the definition of adherence will refer to “the ability 
of the person living with HIV/AIDS to be involved in choosing, starting, managing and maintaining a 
given therapeutic combination medication regimen to control viral (HIV) replication and improve 
immune function” as defined by  Simoni et al, 2003. 
2.3 THE CHALLENGE OF MEDICATION ADHERENCE 
One of the key challenges to better adherence has been both the number of drugs that patients 
have to take as well as their toxicity. Advances in research about HAART have introduced multi drug pills 
that contain two or three drugs in one but with lower toxicity when compared to the previous mono-
therapies (Kalichman and Malow, 2004). These are commonly known as Highly Active Antiretroviral 
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Therapy which has brought longer and healthier lives to PLWHA . This has resulted in lowered patient 
loads in hospital beds, PLWHA leading more productive lives and a marked reduction in annual HIV 
related deaths. 
Studies have shown that for HAART regimens to be effective, strict adherence to prescribed 
dosing schedules is necessary. This is to reach and maintain therapeutic levels of these drugs and prevent 
the development of drug resistant viral strains in the body .However excellent adherence doesn’t always 
result in complete viral load suppression while non adherence increases the risk of death due to treatment 
failure(Chesney, 2003 and 2004). 
In a review of theorising contextual relationships in adherence, (Goudge et al 2004)  and (Gill et 
al2005) mention that missing more than 5-10% is linked to incomplete suppression of viral replication, 
declining CD4 cell counts, clinical progression to AIDS or death and the development of and spread of 
antiretroviral drug resistance to HIV. It has been established that adherence to most chronic diseases 
varies between 33-80% with a mean of 67% of doses taken or prescribed (Paterson et al, 1999:2000) in 
Goudge et al,(2004 ). When it comes to HIV/AIDS the margin between success and failure is narrow. In 
order to maximise the benefits of HAART maximum adherence is required. The unique characteristics of 
the HIV require near perfect adherence with >95% defined as the acceptable level required to achieve 
complete viral suppression (Fogarty et al,2002). The resistant strains of HIV due to non-adherence can be 
transmitted to uninfected patients leaving people who have recently acquired the virus infection and 
previously drug naïve patients without effective options for treatment (Wainberg & Friedland, 1998). 
Liechty & Bangsberg (2003) further state that resistant strains of the virus accumulate most rapidly when 
patients have high levels of adherence but with incomplete viral suppression. 
2.4 MEASURING   ADHERENCE  
Forgaty et al(2002) in a review of published and abstract reports of patient adherence to HIV 
medication regimens reported that methods used to asses adherence fell into three categories: 
i. Subjective measures of adherence based on self report or others’ report of adherence, 
including medical chart review.  
ii. Objective measures of adherence (pill counts, pharmacy refill records, use of mechanical or 
electronic monitors of pill or drug use) and  
iii. Physiological methods or indicators (undetectable viral load, CD4 count, plasma assay or lab 
reports).   
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 The review further noted that most of the studies used multiple methods of assessments, with the 
most frequent being subjective (87.7% of the studies). These used interviews and questionnaires and 
surveys administered by self or others. 
The most reliable subjective method for measuring adherence is the self-reporting (Family Health 
Planning, 2001), where a patient is asked how many doses s/he missed in the last day or two days or two 
weeks. The format of the questions varies from study to study. Non-adherence rates are higher in studies 
where a longer recall time is used. With a longer recall period the chance of inaccuracy increases. Answers 
are influenced by patients’ desire to provide a socially acceptable answer, particularly when the interviewer 
is a health worker whose role has been to exhort the patient to adhere. Other inaccuracies may result 
from imprecise or inconsistent questioning, or patient forgetfulness. The three day recall period has the 
advantage of being moderately shorter compared to similar measures like the seven day or one month 
recall methods that have been used in other studies. This means that the patient can easily recall with 
accuracy the exact amount of tablets taken or missed. This method was further enhanced by asking the 
patients the number of tablets that they had missed the previous day and two days to ensure that the 
results were reliable. The underside to this method is the fact that the patient may desire to provide a 
socially acceptable answer especially where healthcare workers are concerned. Paterson et al(1999;2000) 
suggest that less than a 7-day recall period may not be adequate to determine longer term adherence. They 
proposed that additional questions be used to determine adherence over weekends compared with 
weekdays due to behaviour differing over those two periods. Two studies report that the self-report 
method fails to detect 20-35% of non-adherent individuals (Morisky 1986, Arnsten et al 2001). Despite 
these failings a significant association has been shown between self-reported levels of adherence and viral 
load (Bangsberg et al ,2001; Nieuwkerk et al, 2001; Weidle et al ,1999;Hecht, 1998).  
Pharmacy records can be a convenient measure of adherence assessment in situations in which a 
patient has a single source of antiretroviral medication. However, it may therefore not be absolutely 
reliable because it requires patients to always use the same pharmacy and that they don’t share the pills 
prescribed. Sharing or otherwise would lead to overestimating adherence (Paterson et al, 2002). 
A patient’s viral load can be used as an indicator of possible poor adherence yet there can be 
instances where a fully adherent patient’s viral load is not as low as expected hence as a result poor 
adherence cannot be assumed (Mocroft, 2003). Biological parameters like the Mean corpuscular volume 
(MCV),Uric acid levels and hyperbilirubinemia include some of the biological markers that are reported to 
have been used as crude markers of adherence (Paterson et al ,2002).However there are varying reports of 
the association between these biological markers and the virologic outcome due to the dose response 
relationship variations. These would be inadequate if used to measure adherence. 
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Monitoring of plasma concentrations of drug levels has been indicated as another means of 
assessing adherence. These methods however remain to be standardised especially procedures for sample 
collection, cross validation of analytic procedures and interpretation of assay results (Paterson et al, 2002). 
“White coat compliance effect” or “the toothbrush effect” a situation where increased adherence occurs 
immediately before a clinic visit limits the usefulness of this method to assess adherence. 
Physicians and other health care providers routinely make predictions of the adherence of their 
patients to antiretroviral therapy, especially prior to initiating treatment and when assessing reasons for 
poor adherence outcome (Paterson et al ,1999;2000). Assessments of adherence by health providers are 
often inaccurate and are often no better than chance (Bangsberg et al 2001). Providers don’t have time to 
collect detailed adherence assessments - which pills are being taken less, why, and what times – missing an 
opportunity to help the patient work out a solution. Providers have expectations of patients to adhere, an 
expectation that makes it more difficult for a patient to be open about non-adherence (Bangsberg et al 
2002). 
In the absence of methods that measure adherence perfectly, data triangulation procedures must 
be applied to measure the outcome of interest. Triangulation can be achieved through using multiple data 
sources, different researchers and multiple perspectives to interpret a single issue, program or problem 
(Carel et al, 1995). Thus for the purpose of this study self-reported adherence from patient exit interviews 
will be triangulated with a record review of the patients’ viral load records in order to establish adherence 
levels. 
2.5 HAART REGIMENS IN SOUTH AFRICA 
The benefits and aims of antiretrovirals are summarized in the UNAIDS(2005) summary report that 
includes the ones listed below: 
1. To cause a sustained suppression of HIV multiplication and hence the reduction in the amount 
of virus in the body. In this case the patients viral load should remain undetectable (<400 
copies/ml), and remain so when on HAART. 
2. To restore the body’s ability to fight infections (immunity), improve the quality of life and 
prolong life(i.e. decrease HIV-related morbidity and mortality).The aim is to raise the patients 
CD4 count and remain above the baseline count. This should result in fewer HIV-related 
illnesses. 
3. ARVs can also be used to prevent transmission after exposure to HIV. This is referred to as post 
exposure prophylaxis (PEP). 
4. ARVs are used in the prevention of mother to child HIV transmission (PMTCT). 
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In case of HAART, all drugs consist of a dual nucleoside component and a third potent non-
nucleoside drug to complement it (WHO,2002). There are two recommended regimens in adults for use 
in the South African public sector. These consist of a combination of NNRTIs and NRTIs  with 
PIs(SAHIVS,2002; DoH,2003)  
The first regimen1(a) consist of a combination of Stavudine(d4T)/ Lamivudine (3TC) and 
Efavirenz(EFV).For drug naïve adult patients commencing treatment,d4T (40mg ) is taken every 12 hours 
with 3TC(150mg) every 12 hours and EFV (600mg) at night (SAHIVS,2002; DoH,2005). 
Alternatively, in case of pregnant women or  those who are unable to guarantee reliable contraception 
while on therapy the regimen 1(b) is recommended. Regimen (1b) consists of d4T/3TC and Nevirapine 
(NVP). d4T (40mg ) is taken every 12 hours with 3TC(150mg) every 12 hours and NVP (200mg) daily for 
two weeks followed by 200mg every 12 hours(SAHIVS,2002; DoH,2003).  Patients who continue to fail 
virologically despite demonstrated adherence may be changed to regimen 2. Regimen 2 consists of 
Zidovudine (AZT)/Didanosine (ddl) and, Lopinavir and ritonavir (LPV/r). AZT (300mg) is taken every 
12 hours with ddl(400mg) once a day –taken alone, dissolved in water on an empty stomach and LPV/r 
(400/100mg) every 12 hours (SAHIVS,2002; DoH,2005). 
The Table (1-1)below shows the recommended regimens in the South African public health sector as 
described above.  
Table 1-1: Recommended ARV regimens in South Africa 
Regimen DRUG 
and dosage NRTI NNRTI PI 
1a d4T 3TC EFV  
Dose 1x40mg b.i.d 1x150mg b.i.d 1x600mg qd  
1b d4T 3TC NVP  
Dose 1x40mg b.i.d 1x150mg b.i.d 1x200mg b.i.d  
2 AZT Ddl  LPV/r 
Dose 1x300mg b.i.d 1x400mg qd  1x400mg b.i.d 
 
2.6 PLASMA VIRAL LOAD AND TREATMENT RESPONSE 
With HIV infection, there is usually a rapid increase in plasma viral load. In untreated infection, 
replications usually produce billion of new viral copies daily. Plasma HIV/RNA (viral load) testing 
quantifies the HIV viral burden in the plasma. In resource rich areas of the world with access to viral load 
monitoring, the viral load is a standard tool for used for monitoring treatment response in patients taking 
HAART. In certain situations the viral load maybe a factor into decisions to initiate or change HAART 
(U.S Department of Health and Human services, 2006).Viral load assays include the HIV/RNA 
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polymerase chain reaction, the branched chain DNA and the nucleic acid sequence-based amplification. 
The lowest level of detection differs for each test. Ultra sensitive assays measure viral loads up to 50-80 
copies/mL whereas older assays usually have a cut off at <400 copies/mL. A viral load below the level of 
detection ("undetectable") indicates inability of the assay to detect HIV in the plasma but does not 
indicate absence or clearance of the virus from the body. Suppressing RNA to an undetectable level is an 
important goal of HAART. Viral load is usually checked at regular intervals depending on the patient’s 
clinical situation (Palella et al, 2003). 
Recent studies of the pathogenesis of HIV have increased our understanding of HIV infection. 
Initially thought to be slowly evolving, HIV infection is now understood to be a dynamic process. Very 
high levels of HIV are found within weeks of primary infection (Ho and Alam, 1989). Embretson and 
colleagues(1993) further report that even during the clinically silent period of infection, massive amounts 
of HIV are usually present in the lymph tissue thus indicating that there is no virologic latency. 
HAART is a strategy of ARV treatment that has a reasonable chance of suppressing HIV 
replication completely; suppression is defined as a decrease in HIV RNA plasma levels to below the 
detection limit. Currently, HAART usually involves two NRTIs plus either an NNRTI or protease 
inhibitor, however, double protease inhibitor therapy is also widely used (Henry et al, 1997). It is 
recommended that treatment response should be assessed within first 2 to 4 weeks of treatment. 
Treatment response, as defined by viral load, is usually evident within 2 to 4 weeks and is greatest by 4 to 
12 weeks. However, if the initial viral load is quite high, 12 to 24 weeks may be needed to achieve a 
maximum decrease. 
2.7 DETERMINANTS OF ADHERENCE 
There are several factors which can influence adherence. These have been measured using 
various techniques and methods. The Barriers to Adherence Checklist (BAC) has been developed to 
assess common environmental, physical and social barriers to adherence (Catz, 2000). Holzemer (1997) 
developed a scale to asses the extent of engagement of the patient and the provider, but none focuses on 
the way the patient interacts with the health care provider from the perspective of the Chronic Care 
Model. Under the CCM is where the patient related factors determining adherence are investigated. 
In a review by Fogarty et al (2002), they conclude that the possible factors can be grouped as: 
those relating to treatment regimen, social and psychological factors, institutional resources and personal 
attributes. From the same study by Fogarty(2002), issues that relate to treatment regimen like scheduling 
and cognitive demands and regimen side effects were found to impact on adherence. Other studies found 
institutional resources like access to medication and health services, and personal attributes like age, 
gender and social economic status to be associated with adherence (Orrell et al, 2003). 
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Psychological factors, including the patients’ perception of the provider’s degree of caring can 
influence the ability to comply with the drug regimen. Few studies have examined continuous counselling 
as a form of support for patients that are affected by HIV/AIDS. In a prospective randomised two arm 
study by Tuldra & colleagues in 2000, 116 patients on ARVs were administered a psycho-educative 
intervention to implement adherence. He observed highly consistent adherence levels in the experimental 
group (94%), compared to 69% in the control arm. This was suggestive that counselling could help 
reduce the correlates of poor adherence like poor effort to take medication and self capacity to follow 
regimens. Given the patients reports of depression and fear and anxiety it will be important to examine 
the role played by the quality of counselling in enhancing adherence in patients on ARV and to define and 
monitor certain variables related to adherence in order to enhance compliance to ARVs. 
2.8 STUDY AIM AND OBJECTIVES 
2.8.1 RESEARCH AIM  
To identify factors which affect or limit adherence to HAART among adults on HAART 
in two sites in Gauteng province in 2006. 
2.8.2 RESEARCH QUESTIONS 
1. What is estimated rate of adherence to HAART? 
2. What are the facilitators of adherence to ARVs among patients on HAART? 
3. What constitute barriers to adherence in patients on HAART? 
2.8.3 STUDY OBJECTIVES 
1. To quantify patient adherence to ARVs using viral load response in two selected public 
ARV roll out sites-Natalspruit hospital in the East Rand area (region F)  and 
Empilisweni community health care centre in the region G (the former Vaal triangle) 
both in Gauteng province in 2006. 
2. To determine factors that sustain good adherence in patients attending Natalspruit 
hospital and Empilisweni Community Health centre in 2006. 
3.  To determine the barriers to patient adherence to the Gauteng HAART programme in 
2006. 
4. To determine the relationship between the factors identified and adherence. 
5.  Recommend possible interventions to improve adherence. 
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2.9  DEFINITION OF TERMS 
 Adherence-Adherence to a drug regimen is most commonly represented as the proportion of 
doses prescribed actually taken by the patient. Therefore for the purposes of this study adherence will 
be defined as that proportion of patient on ARVs taking >95% of the doses prescribed by the health 
care giver or having a viral load outcome of <400 RNA copies/ml.. 
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CHAPTER THREE: TOOLS AND METHODS 
3.1 STUDY DESIGN 
 
The study was a cross-sectional study. Exit interview questionnaires were administered to 
patients attending the two public ARV roll out sites in Gauteng province. The study also involved the 
review of patient records to assess adherence to ARVs using viral load data and CD4 counts obtained 
from these.  The study was carried out from August to November 2006. 
3.2 STUDY POPULATION 
 
The study area covered two selected public ARV sites in the Johannesburg Metro area of 
Gauteng province, South Africa in 2006.One was a hospital, Natalspruit, located in the Ekhuruleni 
Metropole and another was a Community Health Centre, Empilisweni, located in Sedibeng region of 
Gauteng province. The study population included all the patients that had been registered at the ARV 
sites in Gauteng province for longer than four months prior to the start of the study in August, 2006. 
3.3 SAMPLING 
 
The study employed a random sampling method. Two pilot ARV roll out sites were randomly 
selected from 28 sites in Gauteng using simple random sampling from the larger study. Interviewees were 
selected randomly during the “HIV/AIDS clinic days’’-when they were scheduled to attend for 
medication at the site. Exit interviews were administered over a 6 week period at each site. All patients 
over 18 years of age who attended the clinic during the 6 week period on designated HIV days were 
eligible for the study. Clinical records of all patients interviewed where then reviewed. The weakness of 
this method was that it only included registered patients still attending the HAART programme. This has 
the effect of underestimating barriers affecting adherence in the public health sector in Gauteng since the 
ones who would most likely give a true picture of non-adherence were no longer in the health care 
system. Further work is still being done by the Centre for Health Policy on following up on those who 
have dropped out in another study.   
The sample size was calculated based on Dobson’s paper (1994). Assuming a 95% level of 
confidence and a 75% response rate, a minimum of 128 interviewees was calculated. A total study sample 
(n=355) was randomly selected from the study population-the two public ARV sites in Johannesburg, 
Gauteng province.  
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3.4 MEASUREMENT TOOLS 
 
This study utilised two research methods: exit interview questionnaires and pharmacy record 
review. Questionnaires were administered to determine the self reported adherence using client exit 
interviews to those attending the two sites. Record reviews were done to eventually determine viral load 
and CD4 count adherence from the pharmacy records. 
3.4.1 EXIT QUESTIONNAIRES  
A patient exit interview questionnaire administered to collect self-report adherence data from the 
patients attending the ARV sites. A total of 355 questionnaires were administered at Natalspruit Hospital 
(n=191) and Empilisweni CHC (n=164). 12 of them were declared invalid and therefore not considered 
part of the study after cross checking for quality. 
The exit interview dealt with 5 main themes namely: 
1. Socio-demographic characteristics of the client 
2. Knowledge of HIV/AIDS and ARVs(Health literacy) 
3. Patient-health provider communication 
4. Adherence to medication 
A brief summary of the various variables within the five sections is given below.  
(The full questionnaire is in Annex E) 
3.4.1.1 Socio-demographic background 
The questionnaire dealt mainly with demographic characteristics of the client in order to build up a 
profile. The client/patient was asked questions that dealt with: 
• gender, 
• highest level of education 
• The type of work they do as well as whether or not they are engaged in any earning activity i.e 
economic or money generating activity. 
•  Whether they were recipient of a disability grant from the provincial government 
• Costs involved in the process of seeking treatment like transport to and from the site, 
accommodation and cost of medication. 
3.4.1.2 Knowledge of HIV/AIDS and ARVs 
In this section the questionnaire dealt with: 
• Whether the client knew what ARVs do 
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• They were further asked to either agree or disagree with several statements in this section e.g. 
Whether ARVs cure HIV/AIDS. These statements were structured according to a 4 point 
Lickert scale. 
3.4.1.3 Patient-provider communication 
This section dealt with structured questions about the experiences of the client at the facility 
where the exit interview was talking place and their interactions with the health care provider. 
This section sought to obtain information about whether: 
• The clients were able to talk in private with the health care provider 
• How many hours they spent at the health care facility. 
• The health care worker was too busy to listen to their problems 
• It was a problem that the health care worker did not speak their language 
• They were provided with feedback on whether the drugs were working or not 
• The health care workers were helpful or not 
3.4.1.4 Adherence to HAART 
This section of the questionnaire sought to obtain information about the how the 
clients/patients were coping with taking ARVs on a regular basis. The information was needed to gain a 
better understanding of the real challenges that people taking ARVs faced in order to gain an insight into 
the barriers to them achieving 100% adherence and to help in the determination of self report adherence. 
Examples questions in this section dealt with the number of tablets taken in a day and the number missed 
within various periods. These involved 24 hour recall, 3 day recall and one month recall periods. These 
were later collated and used to calculate adherence after combining the information with the pharmacy 
record review. Further information was sought about the reasons for missed doses and appointments to 
collect the tablets at the health care facility. 
3.4.2 RECORD REVIEW 
 
Laboratory records were retrieved from patient files at the two ARV sites. The CD4 count and 
viral load was determined from the pharmacy records of the ARV sites where the clients were accessing 
treatment. The data concerning adherence and the physiological markers was collected using specially 
designed data capture sheets. (See annex F). 
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3.5 PILOT STUDY 
 
A pilot study was carried out in a similar setting to the intended study sites. In the pilot study, 
respondents who are were on ARV medication from another site (Helen Joseph hospital) were recruited 
and the questionnaires administered .The pilot study was done to investigate the following: 
1) Test the validity of the questionnaire to measure or assess the outcomes of interest especially 
barriers to attendance and adherence.  
2) Test the understanding of the language in the questionnaires by the interviewers. The 
questionnaire proved to be easily understood since the field researchers were proficient in 
English and IsiZulu (used mostly in Natalspruit) as well as Sotho (used mostly in Empilisweni 
clinic) for translation and back translation purposes   
3) The pilot study was used to determine the logistical requirements for the rest of the study that 
commenced much later in August 2006.During this time the requirements in terms of cost of 
transport, time taken to and from the sites and budgetary estimates for stationery and computer 
facilities were determined from the estimates offered by the field researchers. 
4) The limitations of the questionnaire were analysed and changes made to the questionnaire during 
and immediately after this initial period and thereafter modifications were incorporated in the 
questionnaire. 
3.6 LIMITATIONS AND VALIDITY OF THE STUDY 
 
Given that the study was based on questionnaires to measure the barriers to adherence there are 
several limitations that are bound to arise inherent in questionnaires, some of which are highlighted 
below: 
i. The study was not able to interview patients who had dropped out of the ARV 
programme due to the poor health information systems at either site that could not trace 
them. Patients who had dropped out of the HAART programme would have ideally 
provided the best views regarding the barriers to adherence. 
ii. 85 patients’ viral loads and 38 patients CD4 counts had not been measured. 
To further strengthen the study in terms of validity, several steps were undertaken as outline 
below: These dealt mainly with recall problems and creating a rapport with the respondents among 
others. 
a) Due to recall problems (given the longer recall period of three days) and reluctance of 
respondents to honest about missed doses, the questionnaire may not have been able to 
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properly measure adherence hence the use of patients’ record review of the viral loads to 
ensure that there clear picture of adherence is obtained through triangulation of results. 
b) Given the likelihood of patients’ reluctance to be truthful about missed doses, 
experienced interviewers (all of whom were PLWHA) conducted the interviews. They 
were able to put respondents at ease, establish a rapport in order to encourage 
respondents to be truthful about adherence. 
c) Additionally the interviewers were proficient in Zulu, Sotho and English as well as a 
fourth language in case the respondent preferred it. Employing same language-speakers 
to interview respondents was meant elicit the likelihood of more honest responses.  
d) Structured questionnaires were used to improve the consistency of the questions during 
the interviews.  
3.7 EXCLUSION CRITERIA & DATA MANAGEMENT   
 
There was exclusion at the collection and analysis of data. HAART clients who had been on 
treatment less than 4months were excluded from the study. A database was created using Epiinfo® to 
capture all information. The data was captured using Epiinfo® version 2002 and stored in Microsoft® 
Database format. Data cleaning and processing and analysis was done using computer software; Epiinfo® 
version 2002 and Intercooled Stata 9®.  
3.7.1 ANALYSIS OF DATA 
Triangulation of information from the different sources was done to determine adherence and 
the major themes explored from patients’ perspective. Quantitative and semi-qualitative methods were 
utilized in analysis of data. Descriptive statistics were further used to bolster the qualitative methods. 
Three measures were used to assess adherence. One subjective (3 day recall self report) and two 
physiological methods (CD4 counts and plasma viral load) methods were used to asses adherence.Each 
adherence measure was collapsed into two categories for analysis - high adherence and low adherence. 
Individuals who reported taking 100% of their medication were categorised as highly adherent, while 
individuals who took less than 100% of their prescribed doses of ARVs were categorised as having low 
adherence. The physiological/clinical outcomes were further used as a surrogate measure for adherence 
(Chesney, 2003). High physiologic “adherence” was categorised as those individuals who had a higher T-
lymphocytic CD4 count (>=200) and low plasma viral load (<400 RNA/ml) while lower “adherence” 
included individuals with a low CD4 cell count (<200) and a high viral load (>=400 RNA/ml). Drug 
regimes were classified as either first line (1a and 1b) or second line of treatment according to the 
National Department of health, South Africa (2005) guidelines. 
 24 
 
  Proportions were compared using the two tailed Chi-square and Fisher’s exact tests of association. 
All hypotheses tested were two tailed at a 95% confidence interval (α=0.05). Univariate analyses were 
performed using the Kaplan-Meier survival estimates for each of the exposure variables reported.  To 
estimate the independent effects of selected risk factors on “adherence” as measured by the plasma viral 
load, simple linear logistic regression was used with maximum estimation of the regression co-efficient 
and their confidence intervals. Only crude odds ratios were reported.  
3.8  EETHICAL CONSIDERATIONS 
 
1) Permission was sought and obtained, before start of the study, from the facility level managers 
and provincial department heads to carry out research at the selected sites and to further access 
the records of the clients to obtain data and information regarding viral loads of the duration of 
the study period. 
2) Before the commencement of the research study, ethical clearance was sought and obtained from 
the University of Witwatersrand, Johannesburg to carry out research on human subjects. The 
study was thus found to be of no harm to human subjects by either being risky, invasive or 
embarrassing. 
3) Emphasis was put on informing the respondent of the aims and objectives of the study before 
being asked to give their informed written consent to be interviewed. Written informed consent 
was thereafter sought and obtained before exit interviews could be conducted with the clients at 
the selected ARV sites.  
4) Attention was paid to anonymity and confidentiality by ensuring that the interviews are 
anonymous with no names or other identifiers used except for codes to help in analysis of results. 
Permission was sought from the patient to examine their medical record to extract the viral load 
and CD4 counts. Patients gave interviewers their file number to facilitate this. If a respondent 
was unable or unwilling to provide written consent, verbal consent was sought and they were 
asked to mark with symbols on the information sheet. 
5) The client was informed of his/her right and choice to either participate or to opt out of the 
study at anytime even when the study has commenced and written consent obtained. Six 
prospective interviews refused to be interviewed but offered their files for record review. 
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CHAPTER FOUR: RESULTS 
4.1 CHARACTERISTICS OF RESPONDENTS 
 
  Table 4-1 shows a summary of the socio-demographic, economic and clinical characteristics of the 
participants. From a total of 355 interviews only 96.6% were declared valid with the rest either 
information or informed consent. 
Table 4-1 :  Sample characteristics 
 
Characteristics of respondents Total (%) 
Facility(n=343) Empilisweni 159(46.4%) 
Natalspruit 184(53.6%) 
Gender(n=328) Males 87(26.5%) 
Females 241(73.5%) 
Age(n=340) Mean 36.9 years 
Range 18-70 years 
Level of education(n=343) Formal education 333 (97.1%) 
No formal education 10 (2.9%) 
Earned money in the past week? 
(n=343) 
No 277(80.8%) 
Yes 66(19.2%) 
Do you currently receive a 
disability grant? (n=343) 
No 187(54.5%) 
Yes 156(45.5%) 
At present, do you have medical 
aid? (n=343) 
No 339(98.8%) 
Yes 4(1.1%) 
Do you have electricity in your 
household? (n=342) 
No 47(13.7%) 
Yes 295(86.3%) 
Tell me if your household has any 
of the following appliances that 
are working? Fridge(n=343) 
No 97(28.3%) 
Yes 246(71.7%) 
Radio  (n=343) No 90(26.2%) 
Yes 253(73.8%) 
Cellphone ( n=343) No 98(28.6%) 
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Characteristics of respondents Total (%) 
Yes 245(71.4%) 
Television ( n=343) No 94(27.4%) 
Yes 249(72.6%) 
Does any member of your 
household own any of the 
following? Bicycle ( n=342) 
No 300(87.7%) 
Yes 42(12.3%) 
Donkey/horse ( n=342) No 341(99.7%) 
Yes 1 (0.3%) 
Sheep or cattle (n=342) No 341(99.7%) 
Yes 1(0.3%)) 
Clinical profile Mean S.D Range 
Months on ARV therapy (n=340) 14  7.1 1-47 
CD4 count (cells/ml) (n=343) 208 166 1-1014 
Detected viral load (copies/ml) 
(n=343) 
 
3,457.6 
 
28,846.58
 
1- 460,000 
 
There were similar proportions of respondents from both facilities (1:1). In terms of gender 
(n=349), there were more females than males (a ratio of 5:2). The ages (n=340) of the respondents ranged 
from the youngest (18 years) to the oldest (70 years) old with a mean of 36 years and ten months. The 
majority (97.1%) had attained some form of formal education and only about 19.7% were working 
compared to those who were not. The ratio of respondents with access to disability grants (n=343) to 
those without was almost the same (1:1).Less than 2% of the respondents had access to medical aid with 
the overwhelming majority without medical cover.  
The clinical profile of the respondents suggests that the majority had spent on average one year 
and a month on ARVs. Most had an average T-lymphocyte CD4 count (n=343) of 206 cells per ml with a 
standard deviation of 164.31 and a mean viral load (n=343) of 4,186 RNA copies/ml of blood with a 
standard deviation of 32,437.1. 
4.2 MEASURES AND PROXIES OF ADHERENCE 
This section deals presents data for missing results in the various adherence assessment measures 
respectively. This is followed by a comparison of the various measures and finally a comparison of the 
respondents’ length on treatment with immunological and viral load outcome measures respectively. 
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Virologic “adherence” was the main outcome used as a surrogate marker for adherence. As previously 
mentioned,CD4 counts were discounted due to the design of the study and the correlation of CD4 counts 
with the length on treatment. 
4.2.1 MISSING DATA 
Table 4-2:  Missing self-report data 
Prescribed doses taken in 
last 3days (%) 
Frequency 
(n) 
Overall 
percentage 
distribution 
Valid adherence 
rate (%) 
Lower adherence (<100%) 2 0.6 0.6 
Higher adherence (=100%) 339 98.8 99.4 
Missing data 2 0.6  
Total  343 100 100 
 
  Table 4-2 shows a summary of the univariate analysis of missing data done using Stata®. 
The results (in Table 4-2) show that there was no missing data when self-report as an adherence measure 
was considered. The valid adherence rate was 0.6% and 99.4% respectively for respondents in the low 
and high adherence categories. 
Table 4-3:  Viral load: Missing data 
Virologic outcome 
(RNA copies/ml) 
Frequency 
(n) 
Percentage 
(%) 
Valid Viral load 
distribution (%) 
 
Lower viral load(<400) 
230 67.1  
88.8 
Higher viral load (>=400) 29 8.4 11.2 
Missing viral load data 84 24.5  
Total 343 100 100 
 
  Results in Table 4-3 show that missing data accounted for 24% of the total viral load distribution.  
The valid viral load distribution for the respondents was 88% and 11% for the higher and lower viral load 
categories respectively.    
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Table 4-4:  CD4 count categories: missing data 
 
 
 
 
 
 
 
 
  In the CD4 count categories, the results (in Table 4-4) indicate that missing data accounted for 
11% of the CD4 count distribution. The valid CD4 count distribution excluding the missing data was 
49.5% and 50.5% for the respondents with a lower CD4 count and those with higher CD4 count 
respectively. 
4.2.2 COMPARING ADHERENCE MEASURES 
Table 4-5 :Self-report adherence by Plasma viral load categories 
 
 
   
 
 
 
 
 
 
 
  Analysis of adherence data was done as previously mentioned in the methods section using 
bivariate analysis with viral load as the outcome variable. The results for the viral load outcomes are then 
summarised in tables in this chapter. 
Of the total respondents (n=261), as shown in Table 4-5, 11% had a higher viral load compared to 89% 
with lower viral load. The results further show that of the respondents who reported higher adherence 
(n=260), there was a substantial number (29/262) whose viral load was actually high (11%) indicating that 
CD4 count category Frequency 
(n) 
Percentage 
(%) 
Valid CD4 
distribution (%) 
Lower CD4 
count(<200) 
151 44.0 49.5 
Higher CD4 count  
(>=200) 
155 45.2 50.5 
Missing CD4 counts 
data 
37 10.8  
Total 343 100 100 
Self reported adherence 
Adherence categories 
( n=261;p= 1.000) 
Virologic outcome (RNA copies/ml) 
Higher  viral  load 
(>=400) 
Lower viral load 
(<400) 
Total 
Lower adherence 
(<95%) 
- 2(0.9%) 2(100%) 
 
Higher adherence 
(>95%) 
29(11.1%) 230(88.8%) 260(100%) 
Total 29(11.1%) 232(88.9%) 261(100%) 
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they had over estimated their adherence. The virologic outcome seemed to be a better indicator of 
whether an individual was taking their medication as prescribed compared to the self-report adherence. 
Table 4-6 :Self-report adherence by CD4 count categories(n=309) 
 
 
 
 
 
 
 
 
 Regarding CD4 count as an outcome measure of adherence, the respondents who reported higher 
adherence were more evenly distributed with almost half in the lower CD4 count and higher CD4 count 
categories respectively as shown in the Table 4-6.The two who reported lower adherence had a CD4 
>200.    
4.2.3 MONTHS ON TREATMENT AND DRUG REGIMENS * 
Table 4-7: Months on treatment by plasma viral load (n=263) 
Months on treatment 
 
Plasma viral load categories (RNA copies/mL) 
High (>=400) Low(<400) Total 
< 12 months 14(14.3%) 84(85.7 %) 98(100%) 
12-24 months 11(7.4%) 137(92.6%) 148(100%) 
> 24 months 5(29.4%) 12(70.6%) 17(100%) 
Total plasma viral load 30(11.4%) 233(88.6%) 263(100%) 
 
There was a significant association between the months on treatment and the virologic outcome 
(p<0.05).A comparison of the months on treatment of the respondents with their viral load (in Table 4-7) 
shows that if a patient has been on treatment for longer than a year he/she is more likely to have a lower 
viral load – suggesting that the patients that have been on treatment longer are more adherent.  
                                                 
* previously explained in Table 1-1 
Self reported adherence 
Adherence categories 
(χ2 = 1.973 ;p= 0.498) 
Immunological outcome(CD4 count) 
Lower CD4 
count(<200) 
Higher CD4 
count  (>=200) 
Total 
Lower adherence 
(<100%) 
- 2(100%) 2(100%) 
Higher adherence 
(=100%) 
153(49.8%) 154(50.2%) 307(100%) 
Total 153(49.5%) 156(50.5%) 309(100%) 
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Table 4-8: Months on treatment by immunological outcome (n=310) 
 
  
 
 
 
 
 
 
 The number of months on treatment were significantly associated with the immunological 
outcome (p<0.01) as shown in Table 4-8. These were noted to be statistically significant especially 
between respondents who had been on treatment less than 12 months and those on treatment for longer 
periods (between 12 to 24months or more).Respondents CD4 counts while seemingly low in the first 12 
months tended to rise after a year on treatment and stayed that way as long as respondents were on 
treatment. 
As has been reported earlier, there is no generally accepted gold standard for measuring 
adherence but some studies have reported the use of a combination of measures in order to interpret the 
complex issue that is adherence (Fogarty, 2000). Some cohort studies have demonstrated a strong 
association between HAART and successful virologic outcomes (Deeks et al, 1999) while others showed 
an association between adherence and immunologic outcomes (Paterson  et al,1999; 2000). The results 
above have demonstrated that self-report as a measure of adherence is highly unlikely to estimate the true 
adherence effectively given the tendency of the respondents to over estimate their adherence. The other 
option was to use clinical outcomes (CD4 and plasma viral load) of the laboratory results. In this case, the 
CD4 count was found to be depending on the length of treatment and therefore decreasing its reliability 
in cases where patients have been on treatment for less than a year. 
Therefore due to self-report as a method of determining adherence tending to overestimate 
adherence, the clinical criteria used for adherence estimation-viral load was instead used as a surrogate 
adherence marker in the analysis of factors affecting adherence in this study. 
4.3 FACTORS AFFECTING ADHERENCE  
 This sub-section reports the factors hypothesised to affect adherence or its surrogate, in this case 
viral load including the following: Socio-demographic variables, adherence support, patients’ knowledge 
of HIV/AIDS and ARVs and the quality of the patient-health provider relationship. These are compared 
Months on 
treatment 
(χ2 = 35.3;p<0.01) 
Immunological outcome 
Lower CD4 count 
(<200) 
Higher CD4 count 
(>=200) 
Total 
< 12 months 91(68.9%) 41(31.1%) 132(100%) 
12-24 months 56(34.7%) 105(65.2%) 161(100%) 
> 24 months 6(35.3%) 11(64.7%) 17(100%) 
Total 153(49.4%) 157(50.6%) 310(100%) 
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with the plasma viral load categories-classified as lower (<400 HIV RNA copies/ml) and higher viral 
loads (> 400 HIV/RNA copies/ml) respectively. 
4.3.1 SOCIO-ECONOMIC AND DEMOGRAPHIC FACTORS 
Among the socio-demographic indicators investigated include the facility, gender, age groups, 
education levels, medical insurance, access to disability grants and costs associated with access to 
treatment as well as estimated wealth based on assets in the household. Results for individuals whose 
plasma viral load was available were analysed to determine how they affected plasma viral load as an 
adherence outcome. 
Considering that facility from which the patients were interviewed from-Empilisweni CHC and 
Natalspruit hospital, the results indicate that there were no statistically significant differences between the 
two facilities (χ2 =0.2096;p=0.697). On doing further modelling using logistic regression analysis, it was 
noted however that individuals at Natalspruit were 1.8 times more likely to have a lower viral load 
compared to those from Empilisweni [OR=1.8 95% CI=1.15-2.81] although the differences were not 
statistically significant. There was no significant association (p=0.600) between gender (n=179) and the 
virologic outcome. 
The respondents’ ages were determined from the difference between their dates of birth and the 
dates of the interviews took place. These continuous variables were then categorised into three groups-
18-28 years, 29-39 and those with greater than 40 years and compared to the viral load (χ2 
=3.063;p=0.223). Logistic regression with plasma viral load categories indicated that a greater proportion 
of the 29-39 age (p=0.973) group had a lower viral load and appeared to have better “adherence”[OR= 
1.02; 95% CI=0.32- 3.3].The greater than 40 years age group had a higher viral load (p=0.568) [OR= 
0.71; 95% CI=0.21- 2.3] using the 18-28 years age group as the reference. Of the total (n=254) 
respondents, women (75.6%; p=0.587) at a ratio of 3:1 were seen to be more likely to adhere to HAART 
compared to men (24.4%;p=0.647) when their virologic adherence rates were compared [OR= 1.27; 95% 
CI= 0.53-3.06] but this result was also not statistically significant. 
  The highest education level attained by the respondents was compared to the virologic outcome 
categories: low virologic “adherence” (>400 RNA copies/ml) and high virologic “adherence” (<400 
RNA copies/ml. These categories were grouped into individuals with no formal schooling, primary 
schooling, secondary schooling and those with tertiary schooling. Regarding individuals with no formal 
education, there were none in the lower “adherence” group with 100% (7/7) in the higher adherence 
group. 8.8% (5/57) with a primary level education were in the lower “adherence” category compared to 
91.2% (52/57) in the higher “adherence” group. Similarly only 12.6% (25/198) with secondary level 
education were in the lower “adherence” group compared to 87.4% (173/198) in the higher “adherence” 
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category. However there were none with tertiary level education who had lower “adherence” with both 
individuals (100%) belonging to the higher “adherence” category. Although a majority,88.6%(234/264), 
of the respondents belonged to the higher “adherence” category when education is considered, the level 
of education was not found to be significantly associated with the way the individuals adhered when their 
plasma viral load.(χ2 =1.85 p= 0.672).Similarly there were no significant differences when between the 
two virologic “adherence” categories when medical insurance (χ2 = 0.3890 p=1.000) and access to social 
grants (χ2 =3.66; p=0.057) were considered. 
   The costs associated with treatment were grouped into three categories: low cost (<R15), 
average cost (R15-25) and highest cost (>R25) and compared with respective plasma viral loads. Cost 
(n=185) was found to be significantly associated with the viral load outcome (χ2 = 0.3890 p<0.05). Using 
logistic regression results indicate that individuals who faced the highest cost (> R25) in accessing 
treatment were however the least likely to adhere [p=0.078; OR=0.29 95%CI=0.076-1.14] when 
compared to those who faced average costs of between R15-25[p=0.090; OR=0.33 95%CI=0.095-1.18] 
or the reference group (<R15).  
   Lastly socio-economic status was measured by proxy using a composite asset index which was 
created using principal component analysis of several ranked household items that indicate a level of 
wealth like TVs, telephones cell phones and types of housing among others and then scored to create five 
quintiles indicating the level of poverty. These ranged from 1(the poorest) to 5(least poor). These were: 
Q1=poorest, Q2=poorer, Q3=less poorer, Q4=less poor, Q5=least poor. Socio-economic status was 
thereafter compared to virologic outcomes.  Those in the poorest and the least poor quintile have poorer 
virologic outcomes, although the sample size is very small in the least poor quintile. The results generally 
indicated that there is an association between poverty and the viral load outcome or the surrogate 
“adherence”. (χ2=21.73;p<0.01). 
Further comparisons within the group were done. All the quintiles within the wealth category were then 
compared as summarised in Table 4-9.  
Table 4-9 : Asset quintile by viral load category 
Wealth category χ2=21.73 Plasma viral load categories(RNA copies/ml) 
High(>=400) Low(<400) OR (95% C.I) 
Quintile 1(p<0.05) n=64 17(26.6%) 47(73.4%) 1 
Quintile 2 (p<0.05 )n=79 5(6.3%) 74(93.7%) 5.4(1.85-   15.57) 
Quintile 3 (p<0.05)n=66 2(3.0%) 64(97.0%) 11.6(2.55- 52.54) 
Quintile 4 (p<0.05)n=48 4(8.3%) 44(91.7%) 4.0 (1.2-12.74) 
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Wealth category χ2=21.73 Plasma viral load categories(RNA copies/ml) 
High(>=400) Low(<400) OR (95% C.I) 
Quintile 5 (p=0.909) n=7 2(28.6%) 5(71.4%) 0.90(0.16-5.11) 
  
Most notable is that respondents in quintile 3 were ten times more likely to adhere compared to 
the poorest [OR=11.6 95% C.I(2.55- 52.54)] while those in the quintile 2 were five times more likely to 
adhere when compared to the poorest[OR=5.4 95%CI(1.85-15.57) ].The respondents in quintile 5 
[OR=0.90 95% CI(0.16-5.11)] were however more or less adherent compared to poorest with no 
significant difference between the two groups. The results (Table 4-9) indicate that there statistically 
significant differences in “adherence” between the respondents in the five quintiles when compared 
against the reference group (Quintile 1). Further work needs to be done to assess whether these results 
are, in part, due to starting treatment later in the progression of the disease amongst the poorest quintile.  
Table 4-10 : Months on treatment by asset quintile(n=345) 
 
A comparison of the months by the various asset quintiles (Table 4-10) indicates that there was a 
significant association between the months on treatment and the asset quintiles. Most of the respondents 
in the quintile 1 (48%) who were the poorest had been on treatment for less then 12months compared to 
the rest in quintile 2(58%), quintile 3(59%) and quintile 4 (56%) and quintile 5(51%) who had all been on 
treatment for about more than a year respectively. Their poor “adherence” (quintile 1) could probably be 
explained by the fact that respondents had not been on treatment long enough or had taken longer to 
access treatment compared to the other wealth groups. 
Months on treatment 
[χ2=16.058 ,p<0.05] 
Asset quintile 
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 Total 
< 12 months 30(47.6%) 28(35.4%) 23(34.8%) 24(36.4%) 44(62.0%) 149(43.2%)
12-24 months 29(46.0%) 46(58.2%) 39(59.1%) 37(56.1%) 24(33.8%) 175(50.7%)
> 24 months 4(6.4%) 5(6.3%) 4(6.1%) 5(7.6%) 3(4.2%) 21(6.1%)
Total 63(100%) 79(100%) 66(100%) 66(100%) 71(100%) 345(100%)
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4.3.2 DISCLOSURE AND SUPPORT 
This section presents the results regarding disclosure status and social and medication support that the 
respondents reported from the exit interviews, and the extent to which factors are associated with 
virologic outcomes and by association “adherence”.   
4.3.2.1 Disclosure status  
Figure 4-1: Disclosure status of respondents 
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The results as shown in Fig4-1 suggest that the respondents had high disclosure rates to someone other 
than the health care worker at the health facility with over 95% of the respondents stating that they had 
disclosed to someone else. The three people that the respondents were most likely to disclose to were a 
family member 94% (230/245), spouse/partner 81 %( 199/245) and friend 55% (134/242) respectively. 
The respondents were least likely to disclose to a neighbour 33% (114/346) or religious leader 28% 
(98/346) compared to the rest. Only 4% said they would not disclose to anyone else at all.   
4.3.2.2 Disclosure status by viral load category 
This section highlights the comparison of disclosure and virologic outcome and reasons that 
respondents gave for non-disclosure are shown. Results (in Table 4-11) indicate further that disclosure 
did not significantly affect respondents’ virologic outcomes. Given the importance of disclosure, reasons 
for non-disclosure were analysed and are presented below (Table 4-11). Results (in Table 4-12) indicate 
the major reasons for lack of disclosure by the respondents. 
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Table 4-11: Disclosure status by plasma viral load categories 
Disclosure status Plasma viral load (RNA copies/ml) 
High (>=400) Low  (<400) Total 
Apart from health workers have 
you told anyone about your HIV 
status (χ2 =1.273;p=0.259) 
No  - 10(100%) 10(100%)
Yes 27(11.3%) 211(88.7%) 238(100%)
 Spouse/partner if you have one 
(χ2 =0.938;p=1.000) 
No  4(10.8%) 33(89.2%) 37(100%)
Yes 17(11.5%) 131(88.5%) 148(100%)
Family member 
(χ2 =0.42;p=1.000) 
No  1(6.3%) 15(93.7%) 16(100%)
Yes 28(11.4%) 218(88.5%) 246(100%)
Friend 
(χ2 =0.29;p=0.692) 
No  14(12.4%) 99(87.6%) 113(100%)
Yes 15(10.3%) 131(89.7%) 146(100%)
Neighbour 
(χ2 =0.13;p=0.836) 
No  20(11.7%) 151(88.3%) 171(100%)
Yes 9(10.2%) 79(89.8%) 88(100%)
Religious leader 
(χ2 =1.09;p=0.387) 
No  23(12.5%) 161(87.5%) 184(100%)
Yes 6(8.0%) 69(92.0%) 75(100%)
 
 
Table 4-12: Reasons for non-disclosure 
Do you keep your status secret for any of 
the following reasons:  (n=337) 
 
No (%) 
 
Yes (%) 
fear of rejection by  family  281(83.4%) 56(16.6%) 
fear of rejection by friends 189(56.1%) 148(43.9%) 
fear of violence   164(48.7%) 173(51.3%) 
I do not trust people   89(26.4%) 248(73.6%) 
I will not get help from others if they know 
my status 
89(26.4%) 248(73.6%) 
fear that I will be stigmatised  97(28.8%) 240(71.2%) 
fear that people will  gossip about me 93(27.6%) 244(72.4%) 
fear that my HIV status will be known by the 
community 
88(26.1%) 249(73.9%) 
 36 
 
Do you keep your status secret for any of 
the following reasons:  (n=337) 
 
No (%) 
 
Yes (%) 
fear that my partner will know and ask me  
to explain  
249(73.9%) 88(26.1%) 
 
The most important reasons for lack of disclosure were mainly due to the following: 
a. The fear that their HIV status would be known by the community (73.9%). 
b. The fear that they would not get help from any other person who may know their status 
(73.6%). 
c. Lack of trust of other people (73.6%). 
d. Fear of violence (51.3 %). 
This is mainly seen when gender differences were investigated (n=220). When respondents were asked 
whether their HIV status had been disclosed to others without their consent, there were statistically 
significant differences between the genders (χ2 =10.74;p<0.05). Men were 3.2 times more likely to have 
had their HIV status disclosed to other people without their knowledge compared to women in this study 
[OR=3.2 95% C.I(1.5- 6.8)]. There were no major differences between the genders when fear of not 
getting help (χ2 =0.63;p=0.43), lack of trust(χ2 =0.63;p=0.43) and fear of violence(χ2 =1.38;p=0.24) were 
analysed further. This would probably explain the fear that most of the respondents had that their HIV 
status would be known by the community when gender differences are considered especially in men. This 
could possibly explain their low access rates to HAART compared to women. There is a clear split 
between disclosure rates in the family and public contexts as seen by low rates of family people that were 
not disclosed compared to those in the community level (table 4-11).The pattern is further reflected in the 
reasons for non disclosure. In that respondents’ rates of disclosure were very high to members of the 
family but low to those of the public. This was further reflected by fewer proportions of members who 
did not disclose to their families as compared to those who disclosed to the public e.g only 16% feared 
that rejection by family (in the family context) compared to 74% who feared that the community knowing 
their HIV status.   Results showing the extent of support that the respondents received from the support 
groups at the health facilities are shown below (Table 4-13). 
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4.3.2.3 Support group services 
Table 4-13: Support group services by plasma viral load categories 
Services offered at support groups 
(n=32) 
Plasma viral load (RNA copies/ml) 
High (>=400) Low(<400) Total 
Advice and information on 
staying healthy e.g .nutrition, 
exercise & prevention  
(χ2 =0.342;p=1.000)  
No  
- 3(100%) 3(100%) 
Yes 
3(10.3%) 26(89.7%) 29(100%) 
ARV information:CD4 counts, 
ARVs, viral load  
(χ2 =0.342;p=1.000) 
No - 3(100%) 3(100%) 
Yes 3(10.3%) 26(89.7%) 29(100%) 
Treatment buddies 
(χ2 =0.927;p=1.000)  
No  - 7 (100%) 7 (100%) 
Yes 3(12.0%) 22(88.0%) 25 (100%) 
Help with collecting medicines 
from the clinic (χ2 
=0.007;p=0.935)  
No  1(10.0%) 9(90.0%) 10 (100%) 
Yes 
2(9.1% 20(90.9%) 22 (100%) 
Home visits (χ2 =1.734;p=0.188)  No  - 11(100%) 11 (100%) 
Yes 3(14.3%) 18(85.7%) 21 (100%) 
Food (χ2 =2.265;p=0.132)  No  - 13 (100%) 13 (100%) 
Yes 3(15.8%) 16(84.2%) 19 (100%) 
Income generating activities 
 (χ2 =0.521;p=0.589) 
No  1(5.9%) 16(94.1%) 17 (100%) 
Yes 2(13.3%) 13(86.7%) 15 (100%) 
Individual counselling and 
emotional support 
(χ2 =0.764;p=1.000) 
No  - 6 (100%) 6 (100%) 
Yes 3(11.5%) 23(88.5%) 26 (100%) 
 
The services that were offered at the support groups were generally not found to affect virologic 
outcomes, in part because of the small numbers of individuals attending support groups.  Based on the 
respondents’ responses (either yes or no), medication support is reported below (Table 4-14). Patients 
were asked whether they were visited, sent an sms/called by telephone, given food to take with their 
medication, provided transport money or emotional support in order to determine the form medication 
support took.  
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Table 4-14: Medication adherence support 
Do you receive any of the following help or 
support from your friends or family to help 
you take your tablets regularly? 
Patient’s Response 
No Yes 
they visit  you  (n=343) 155(45.2%) 188(54.8%) 
they send an sms or call you by phone(n=349) 169(48.4%) 180(51.6%) 
they give you food to take with your pills(n=349)  84(24.1%) 265(75.9%) 
they provide transport  money(n=349) 71(20.3%) 278(79.7%) 
they provide emotional support(n=349) 33(9.5%) 316(90.5%) 
 
A large majority received emotional support(90%),transport money(80%) and food to take with 
their pills(76%) and to a lesser extent were visited (55%) or sent and sms/called by phone (52%) to take 
their medication as a reminder. It seems that patient’s were much more likely to receive support from 
family or friends than attend a support group. On the other hand there was a significant association 
between disclosure and emotional adherence support (χ2=6.7453;p<0.05) suggesting that the respondents 
received emotional support as the most common form of adherence support after disclosing to a family 
member. Support from family (χ2=0.4197; p=0.517) and friends (χ2 =0.2867; p=0.592) respectively was 
however not significantly associated with plasma viral load suggesting other reasons responsible for 
adherence in this instance. 
4.3.4 KNOWLEDGE OF HIV/AIDS AND ARVs  
Knowledge of HIV/AIDS (health literacy) was used as a proxy for the cognitive demands the 
patient had to be aware of regarding HIV/AIDS management using ARVs. The objective was to 
determine whether the patient had enough information to help them cope with the ARV regimens and 
what was expected of them when on ARV treatment. Their responses were categorised as either correct 
or incorrect and further investigated. 
A majority of the respondents (Fig 4-2) answered correctly when asked questions like for 
example “its acceptable to stop ARVs when one no longer suffers from opportunistic 
infections”99.1%(340/343); “After a couple of years one can stop taking ARVs” 99.4%(339/341),“ARVs 
cure AIDS” 97.2%(317/326) or “people receiving ARVs can transmit HIV to other people through 
unprotected sex”(98.8%) which were to be answered as either true or false responses. 
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4.3.4.1 Patient health literacy responses  
Figure 4-2: Patient knowledge of HIV/AIDS and ARVs 
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4.3.4.2 Health literacy 
 
Table 4-15:  Health literacy by viral load categories (n=240) 
Knowledge  question Response Plasma viral load (RNA copies/ml) 
High 
(>=400) 
Low (<400) Total 
Can you tell me about what ARVs 
do? (χ2 =0.507;p=0.702)(n=244) 
Incorrect 1(6.2%) 15(93.8%) 16(100%) 
Correct 29(12.2%) 209(87.8%) 238(100%) 
Its is acceptable to stop ARVs 
when one no longer suffers from 
opportunistic infections 
(χ2 =0.128;p=1.000) (n=262) 
False 30(11.5%) 231(88.5%) 261(100%) 
True - 1(100%) 1(100%) 
ARVs cure AIDS 
(χ2 =0.917;p=1.000) (n=248) 
False 28(11.6%) 213(88.4%) 241(100%) 
True - 7(100%) 7(100%) 
Missing a few tablets of ARVs is 
acceptable (χ2=0.129;p=1.000) 
(n=242) 
False 30(12.5%) 233(87.5%) 240(100%) 
True - 1(100%) 1(100%) 
After a couple of years one can 
stop taking ARVs 
(χ2 =0.1321;p=1.000) (n=258) 
False 30(11.7%) 227(88.3%) 257(100%) 
True - 1(100%) 1(100%) 
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Knowledge  question Response Plasma viral load (RNA copies/ml) 
High 
(>=400) 
Low (<400) Total 
People receiving ARVs can still 
transmit HIV to other people 
through unprotected sex 
(χ2 =1.642;p=0.272) (n=258) 
False 1(33.3%) 2(66.7%) 3(100%) 
True 28(11.0%) 227(89.0%) 255(100%) 
 
There were no significant differences between the two individuals who gave a “true” or “false” 
response across the two “adherence” categories when asked the knowledge questions (Table 4-15).  
4.3.5 PATIENT-HEALTH PROVIDER COMMUNICATION 
 
The patient- health provider communication was investigated by examined by asking the respondents 
several questions. They were asked to choose between one of five responses to weighted statements on a 
Lickert scale. These were categorised into whether the respondent agreed or disagreed with the statement, 
or was neutral, or found the question not relevant to them. Responses that found the statement not 
relevant, that were neutral or missing were excluded from analysis.  
4.3.5.1 Assessment of patient-provider communication 
Figure 4-3: Patient provider communication 
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  Patient-health provider communication (n=240) was generally uniform with most of the 
respondents agreeing to the questions that were asked. A majority agreed that the health care worker 
(HCW) gave them feedback on HAART (97%), that the HCW discussed the treatment fully with them 
(91%) and that they found it difficult to tell the HCW whenever they missed taking their tablets (58%).An 
equal proportion indicated that the HCW was too busy to listen to their problems and only 8% agreed 
that the queues at the facility were long to see a nurse or doctor.  
   A comparison of the questions asked was made across the “adherence” categories to determine 
any associations across the “adherence” groups (Table 4-16). The results as shown in the table below 
seem to suggest that the quality of care in terms of patient–provider communication may have not 
affected the way the patients took their medication as measured by their viral loads in a significant way.  
4.3.5.2 Patient-provider communication by plasma viral load categories 
Table 4-16: Patient-provider communication by plasma viral load 
Patient-health provider communication question Plasma viral load (RNA 
copies/ml) 
High(>=400) Low(<400) 
The health worker didn’t discuss treatment fully 
with you, including how it works and side 
effects (χ2 =0.11;p=1.000) 
Disagree 27(11.4%) 209(88.6%)
Agree 2(9.1%) 20(90.9%)
You find it difficult to tell HCW when you have 
missed taking your tablets (χ2 = 0.33;p= 0.567) 
Disagree 12(9.8%) 111(90.2%)
Agree 11(12.2%) 79(87.8%)
The health worker provided feedback on 
whether drugs were working or not (χ2 
=0.91;p=1.000)  
Disagree 0 (0%) 7(100%)
Agree 29(11.5%) 223(88.5%)
The health worker was too busy to listen to 
your problems  (χ2 = 0.28;p=0.669) 
Disagree 23(12.2%) 165(87.8%)
Agree 7(9.9%) 64(90.1%)
The queues to be seen by a doctor/nurse are 
too long at this facility (χ2 = 0.25;p=0.713) 
Disagree 3(14.3%) 18(85.7%)
Agree 26(10.7%) 216(89.3%)
Some staff don’t treat patients with sufficient 
respect(χ2 =0.02;p=0.891) 
Disagree 18(11.6%) 137(88.4%)
Agree 12(11.3%) 94(88.7%)
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4.4 REASONS FOR NON ADHERENCE 
This section presents the patient related reported barriers to “adherence”. Asked whether there 
has ever been a month when the respondents could not come to the clinic for the monthly visit (n=259), 
the majority 87% replied in the negative but the rest agreed (12%). These responses were however not 
significantly associated with the viral load (p=0.681). Asked about the frequency of missing, all of them 
said they had missed at least one appointment (n=37) excluding those who couldn’t remember. Patients 
then gave reasons why they missed facility appointments and missed dosages.  
The results (Fig 4-4) suggest that the three most commonly cited reasons for missing facility 
appointments were the following: 
a. Sickness (19.6%). This would probably have been due to respondents suffering from the adverse 
effects of the drugs a common reason given during the piloting of the questionnaire to a focus group. 
b. Being out of town(19.6%) and  
c. Having no transport money (17.9%) but other reasons (19.6%) accounted for a large percentage of 
the barriers to accessing treatment at the facilities. 
The respondents were least likely to miss appointments either because they were working or simply 
forgot. 
4.4.1 REASONS FOR MISSING FACILITY APPOINTMENTS 
Figure 4-4: Reasons for missing Facility appointments 
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4.4.2 DAYS MISSED DOSES AND REASONS 
The respondents were further asked to determine the longest time they had missed their medication 
which were further analysed by drug regimens and asset quintiles as shown in Tables 4-17 and 4-18 
respectively.  
Table 4-17: Longest days missed tablets 
If you didn’t miss any tablets in the last three days, 
when was the last time you missed? 
Frequency  % 
Week 6 1.7 
2 weeks 8 2.3 
3 months 5 1.5 
more than 3 months ago 22 6.4 
never missed 302 88.1 
Total  343 100 
 
A majority (88%) of the respondents reported never having missed a day in taking their medication while 
of those who missed, most reported missing taking their medication more than 3 months ago 
(6.4%).Table 4-18 shows the longest days missed by drug regimens. 
Table 4-18: Longest days missed by drug regimen†(n=327) 
Longest time missed 
any tablets (days) 
[χ2 =16.891;p<0.05] 
Drug regimen
Regimen 1a Regimen 1b Regimen 2 Total 
Never missed 270(92.5%) 25(96.2%) 5(55.6%) 300(91.5%) 
1-10 days 15(5.1%) 1(3.8%) 3(33.3%) 19(5.8%) 
> 10 days 7(2.4%) - 1(11.1%) 8(2.5%) 
Total 292 (100%) 26(100%) 9(100%) 327(100%) 
 
The respondents responses regarding drug regimens (n=327) indicated that 89% (292/327) were on 
regimen 1a, 8% (26/327) on regimen 1b with the rest (9/327) on regimen 2. 
                                                 
† Regimens previously explained in Table 1-1 
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Categorising those who had missed into three categories as shown in Table 4-18 showed that respondents 
on drug regimen two or regimen 1a  were more likely to miss and this was highly significant(p<0.05). 
These were also more likely to miss for between 1-10 days as compared to the rest of the days. 
Table 4-19: Longest days missed by asset quintile 
Longest time missed 
tablets (days) 
[χ2 =16.891;p<0.05] 
Asset quintile 
1 2 3 4 5 Total  
Never missed 57(96.6%) 71(94.7%) 51(82.3%) 59(95.2%) 63(91.3%) 301(%)
1-10 days 1(1.7%) 2(2.7%) 9(14.5%) 1(1.6%) 6(8.7%) 19(%)
> 10 days 1(1.7%) 2(2.7%) 2(3.2%) 2(3.2%) - 7(%)
Total 59(100%) 75(100%) 62(100%) 62(100%) 69(100%) 327(100%)
 
 The Table 4-19 above shows a comparison of the longest time respondents missed their tablets 
and the asset quintile categories. The results indicate that the poorer groups(quintile1,2 and 3) were more 
likely to miss their tablets compared to the less poorer groups (quintile 4 and 5) with a significant 
association to the number of days missed(p<0.05).  
The five most frequently cited reasons for missing to take medication (n=310) were: 
i. Forgetfulness or didn’t have the medication with me (16.7%), 
ii. Don’t believe the medication will work or don’t care or irresponsible (13.7%), 
iii. Alcohol abuse (9.6%), 
iv. Very sick or side effects (9.0%) and 
v. Other reasons or don’t know (34.6%) . 
Stress or depression (1.8%) and having the wrong information (5.1%) were the reasons least 
likely to be cited for missing taking the medication. 
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CHAPTER FIVE: DISCUSSION 
5.1 CCM MODEL: PRODUCTIVE INTERACTIONS 
This report adopts the CCM‡ framework (developed by Wagner and colleagues) to assess 
adherence to HAART and whether it can be used as a possible intervention towards the chronic illness 
disease management in the health care system. Wagner (2001) views the health care team as part of the 
health system which form part of the much larger community (fig 2-1). In his study, Wagner argues that 
chronic illnesses care is characterised by a series of continuous relationships through time with the health 
care team, individualisation of care according to patients’ needs and values, based on evidence and 
cooperation among clinicians in order to optimise patient health outcomes. The health care team helps 
the patients set goals and solve problems, reviews data on course of management, applies clinical and 
behavioural interventions to prevent complications and ensure continuous follow up. The patients on the 
other hand are more involved if they are empowered and acquire skills to confidently take part in their 
health care management thus leading to the so called “productive” interactions. 
Figure 5-1: An Operational framework for chronic health care 
 
 
This study draws from the CCM framework to determine challenges that HAART patients face 
in a health care system largely designed to cater for acute illnesses with regards to adherence to 
antiretrovirals in order to provide evidence base to operationalise the model.  
                                                 
‡ previously discussed in chapter 2.1 on page 9 
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Five selected patient side themes were explored in this research which form part of the elements 
within the CCM framework as indicated in fig 5-1. These included adherence support, health literacy and 
disclosure rates that constitute the elements of an informed and activated patient to engage with 
confidence in the chronic health care system. Either of two possible outcomes can result depending on 
how the interactions with the health system part occur as shown above (fig5-1). 
5.2 ADHERENCE MEASURES 
This report describes the results of a study that determined factors that affect ARV medication 
adherence at two public sites in Gauteng province in South Africa. For purposes of this study, adherence 
was assessed using one subjective method (the self report) and two physiologic indicators (CD counts and 
plasma viral load). The main surrogate marker for adherence was plasma viral load due to limitations of 
the self-report method.  
 In other studies using the self report method- Ammassari (2001), Murri et al , (2000), Haubrich et al 
(1999) have reported that poor adherence is linked to viral suppression. In this study the proxy adherence 
rate was determined by measuring the estimated virologic outcome. The proxy adherence rate was 89% 
which was consistent with similar studies (Bangsberg et al, 2000; Chesney, 2000 and Liu et al, 2001). 
Although these findings are consistent with the adherence rates for chronic diseases (Paterson et al, 
2000), they are way below the acceptable range (greater than 95% adherence) for achieving complete viral 
suppression in HAART as suggested by Chesney (2003). Other studies done in the developed countries 
state that the percentage of patients who can be classified as adherent to ARV therapy ranges from 50-
90%, with the average around 75%. These studies involved the administration of questionnaires to 
patients at HIV clinics or AIDS service organizations with some using record reviews (WHO, 2005). In 
the developing world evidence from Uganda, South Africa and Botswana, as well as other African 
countries indicates that adherence levels range from 60-80% (WHO, 2005). On the other hand 12% of 
the respondents had sub-optimal ‘adherence’ rates. This result was way below the internationally 
acceptable levels of adherence (Singh et al, 1999; Fogarty, 2002;Paterson et al, 1999;2000; Goudge, 2004). 
This therefore calls for strategies that are aimed at patients on HAART in the public health care 
sector especially in the light of the few available treatment options. These may include regular monitoring 
and evaluation of comprehensive HAART programmatic interventions which are important components 
of HAART programmes. The cross sectional nature of this study highlights the need for a more robust 
method to assess adherence rates for example a longitudinal or intervention (RCT) study which would be 
able to investigate the causal nature of non-adherence and produce stronger evidence . 
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5.3 PATIENT FACTORS AFFECTING ADHERENCE 
The facility, gender, age groups, educational levels and access to social grants were not found to 
be significantly associated with the plasma viral load outcome. However these findings are consistent with 
earlier studies done elsewhere (Fogarty et al,2002; Chesney, 2000) that socio-economic factors are not 
associated with successful adherence outcomes. The more important aspect in the gender category was 
that women who accessed HAART services far outnumbered men by a ratio of 3:1 and were more likely 
to adhere compared to the men 20% of the time. This was often attributed to the larger numbers of  
women who were more familiar with the health care system compared to the men as they interact with it 
when accessing other services-antenatal and family planning services (Muula et al, 2007). Muula (2007) 
further suggested that the women’s familiarity with the health care system was more likely to work in their 
favour by facilitating access to the HAART services as they had greater interaction through family 
planning and maternity services. On the other hand men were thought to be slower in uptake of HAART 
services due to the stigma which was as a result of the belief that they would be thought of as having 
acquired the infection outside the marriage. This fact is borne out by the fact that women are generally 
perceived to be infected by their own spouses as reported in another Southern African country (Moon et 
al, 2002).This study however found that the main reason was more to do with stigma in its various forms. 
This would be attributed to the reason that men feared their HIV status would be disclosed to someone 
else without their consent. 
The SES however was strongly associated with “adherence” especially when categorised into four 
categories or quintiles based on the analysis of their household assets. There was a general trend in the 
SES categories indicating that the least poor were more likely to have a poorer virologic outcome 
compared to those not as poor indicating a possible poorer adherence rate as well. This could be 
attributed the high costs of accessing treatment suggesting possible significant financial barriers to 
accessing treatment at the health facilities. 
 Younger individuals were more likely than the older individuals (>40years) to adhere. It was 
however noted that the younger age groups in the 29-39 range were the most likely to adhere followed by 
the 18-28 age group. It would be interesting to determine how and what motivates individuals of 
particular age group to adhere and others not to adhere.  
ADHERENCE SUPPORT 
Adherence support is facilitated when there exists communication between the patient and the 
treatment supporter (in most cases a close member of the family or spouse). This can only occur with 
disclosure being the first step in the support process. In this study most of the respondents had disclosed 
to at least someone other than the healthcare worker. The majority were more likely to have disclosed to a 
family member. The disclosure status was however not found to be significantly different across the two 
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“adherence” groups (Table 4-11). The respondents were further asked their reasons for non-disclosure 
and several reasons were given that were consistent with the view that disclosure carries with it some 
risks. The main reasons advanced for non disclosure were mainly either fear that the respondents HIV 
status would be known by the community, fear that they would not get help from any other person who 
may know their status, lack of trust or fear of violence among mostly the women. These reasons are 
consistent with other studies done about disclosure and its risks (Orumazu, 2000; Klitzman, 2004). The 
responses to disclosure question generally indicate that there is a big problem of stigma in the community 
at large and it would be therefore be important to have programmes in place by the provincial and 
municipal governments that encourage the disclosure of HIV positive persons and their acceptance by 
their families and community at large. This however contrasts with disclosure to family members which 
were quite high perhaps indicating that the stigma existed more outside the family set up especially in the 
community. 
  Adherence to HAART medication was also associated with the support group services offered at 
the facilities where the respondents accessed their medication but the results were not statistically 
significant. Support group services offered included: advice and information on staying healthy, ARV 
related health literacy, individual counselling and emotional support from treatment buddies. Medication 
adherence support generally took the form of visitation, reminders to take medication by calling 
respondents or sms, or providing emotional support. Some received food to take long with their pills or 
transport money to access their pills at the health facility most likely from their family members.  
KNOWLEDGE OF HIV/AIDS & ARVS 
Knowledge of HIV/AIDS (health literacy) was measured by asking respondents about various 
treatment related questions about adherence. On one hand, from the results in this study, numbers of 
years of schooling were not significantly associated with the virologic outcome. On the other hand, 
respondents generally gave the correct responses to the knowledge questions indicating that they had 
adequate knowledge regarding HIV/AIDS, ARVs and adherence related issues regardless of the level of 
education. This indicates the generally thorough treatment preparation that’s done before the patients are 
accepted onto the HAART programme(Dr. Lintso Morena, personal communication,25th September,2007))This 
was consistent with studies by Kalichman et al(1999) and Kalichman & Rompa(2000) who demonstrated 
that health literacy in addition to years of education were independent predictors of treatment adherence. 
They also suggested that people of lower education and lower literacy were 3-4 times more likely to 
default on medication over a 2 day recall period. They further suggested that low health literacy is 
important in adherence to HAART and must be considered, in addition to level of education, as a 
reasonable marker for potential non-adherence. Even in people with more than 12 years of education the 
risk of non-adherence should be determined before commencing treatment as well. Miller et al, 2003 
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further suggested that due to knowledge deficits after treatment initiation clinicians, should still assess 
patients’ understanding of medication dosing soon after regimen initiation or change. 
PATIENT-HEALTH PROVIDER COMMUNICATION  
On one hand, the respondents generally rated well the relationship between them and their health 
care providers with most rating it as either good or excellent when asked. As can be seen from this study 
most respondents generally agreed that the health care providers’ feedback on whether the drugs were 
working or and  health care workers discussed the treatment fully with them especially how ARVs work 
and their side effect which are a crucial aspect for HAART preparation and ongoing treatment. On the 
other hand some of the respondents had missed some doses but did not indicate that to the interviewers 
pointing to a level of dishonesty in the respondents. This was mainly due to the fact that their clinical data 
indicated otherwise especially from the pill counts This may possibly explain that respondents were 
generally rating the way the health providers were communicating with them but not the other way round 
or they viewed this type of communication as a one way issue to help explain the high levels of agreement 
among the respondents. 
Studies have established that doctor-patient communication is regarded as an essential part of 
successful medical care. This is because it’s the main method by which information can be exchanged 
between the two parties. Aspects of the doctor-patient communication may result in desirable patient 
outcomes like influencing patients’ behaviour and well being e.g. satisfaction with care, adherence to 
treatment, recall and understanding of medical information, coping with disease and better quality of life 
or state of health (Ong et al, 1995). Research has shown that better patient-health care provider 
relationships result in better adherence rates. It has been suggested that patients with chronic illnesses 
almost always want as much information as possible while the physician on the other hand seems to 
underestimate the patients’ desire for information. This could be due to lack of agreement between the 
way the patients and the physicians perceive the disease. Physicians who see their relationships as a 
partnership have a more satisfied patient compared to physicians who have a more authoritarian 
relationship (Anderson & Zimmerman, 1993). As further confirmed by Bakker et al(2000) patients who 
are more engaged with their health care providers will report greater adherence to medication regimen 
and provider advice while those who miss at least one appointment point to significantly less engagement. 
5.4 REASONS FOR NON-ADHERENCE 
These mainly refer to reasons that hinder (barriers to) medication adherence that were 
investigated at two levels. On one hand, there was the assumption that there were barriers to accessing 
ARVs from the health facility by the respondents and on the other missing doses of the medication due 
to different reasons related to the patient’s lifestyle. This was based on the framework suggested by van 
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Servellen & colleagues in 2004 that there are individual and system level factors associated with treatment 
non-adherence in HIV infected men and women. 
At the individual level most respondents said that they missed medication due to forgetting or 
didn’t believe that the medication will work, alcohol abuse, side effects or stress and depression. 
Consistent with similar studies forgetfulness emerged as the most common reason cited by the 
respondents for missing to take their medication (Chesney et al, 2000; Weiser et al, 2003). It can be 
argued that forgetfulness was indeed a reason that could be related to alcohol abuse, stress or lack of 
belief that the medication will work. This could help explain why most individuals reported forgetfulness 
as a reason for not taking their medication. The side effects of the medication itself are expected and 
more to do with the regimen demands that arise depending on the line of treatment one is on as reported 
by Harry Nyatela (Centre for Health Policy,November;2006 personal communication ) as a result of 
subsequent qualitative  interviews with a subset of patients . 
This study has also shown the high costs of accessing treatment as a barrier to adherence. In this 
case it could be explained by the mostly unaffordable monthly cost implications for accessing HAART at 
the health care centres by both sexes. 
Other individual barriers to adherence include stigma as observed from the low rates of 
disclosure. The main reasons that pointed to stigma were mainly either fear of not getting help from other 
people who may know the patients’ HIV status, fear of their HIV status being known by the community 
of fear of gossip. Other indicators of stigma were lack of trust of people by the patients. These reasons 
indicate that the respondents generally viewed stigma as coming from community as opposed to the 
family set up. This is evidenced by the low numbers of respondents who feared members of their own 
family knowing about their HIV status compared to the ones fearing community members. 
Regarding missing clinic appointments most respondents cited sickness, being out of town, 
having no transport money and mixing up dates as common reasons for not going to the health facility. 
Sickness was the most common reason that was cited for missing facility appointments in this study. It 
can be deduced that the major reason the respondents would be sick due to either the onset of 
opportunistic infections or adverse effects but more likely the latter. Side effects have been well 
documented ranging from nausea, vomiting, diarrhoea, abdominal pains, headaches, skin rashes, fatigues 
and dizziness (Pakendorf, 2005).  
Finally, this study also confirmed another reason that has been cited by other studies as 
responsible for non adherence. This is the poor access to the health care system by men when compared 
to the women. In the case of men, they were fewer on HAART due to poorer uptake of voluntary 
counselling and testing services that served as the entry point into the HAART and health care system.   
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CHAPTER SIX: CONCLUSION AND RECOMMENDATIONS 
6.1 CONCLUSION 
The proxy adherence rate of 89% that was determined using the surrogate adherence marker for 
adherence in this study compares favourably with several similar studies. However this rate is generally 
low for good clinical outcomes when compared to the recommended level of >95% adherence from 
other studies. This however should be considered as the minimum adherence rate. Adherence generally is 
a complex issue and therefore involves more than one approach to address the barriers as well as the key 
facilitators. Moreover determining adherence is limited by the methodological difficulties of adherence 
assessment that still exist. Since there is no agreed upon gold standard for adherence assessment. 
Factors that favour adherence include medication adherence support. This form of support 
included provision of food, transport and emotional support from close family members. 
The barriers which were identified were the following: lack of transport money to the health care 
facilities for the monthly medication trips, extended absence from the home or town where the patient 
lives, sickness associated with side effects and opportunistic infections, forgetting to take the medication 
as prescribed, stress and lack of self-belief that the medication will work and stigma from the community 
and people to whom the patient has not disclosed.   
 
RECOMMENDATIONS 
These recommendations are based on the bottlenecks to adherence noted in the study and 
should be considered as the minimal interventions necessary to improve adherence. The interventions can 
be effected at the individual, health facility and health system level as outlined below. 
At the individual level, couples embarking on HAART that are in a relationship should be 
advised or encouraged to disclose to one another in order to reduce the fear and stigma surrounding 
stigma  as well as increase adherence support for the long term.  
      Increase support for health literacy and empowerment of both men and women regardless of 
the education levels of the patients. This should be done before they embark on HAART programmes as 
well as being on an ongoing basis in order to asses the risk of non adherence given the increasing risk of 
resistance to antiretrovirals.  
Similarly efforts should be made to involve more patients in the decision making process 
regarding treatment regimens and dealing with the toxicity thereof to help increase belief in the self 
efficacy of the medications. Additionally in order to deal with the lack of belief that the medicines don’t 
work or self-efficacy it would be important to develop practical guidelines to implement adherence 
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management strategies. For example ensuring continuous adherence counselling of the patients, health 
education and assessment of patient knowledge levels thereafter, using practical devices to remind 
patients to take their medication on time (these though should be easily affordable or subsidised for 
patients in the public health sector). Adherence counselling should emphasise and teach stress coping 
interventions especially to discourage alcohol abuse among both men and women so that related 
incidences of forgetting to take medication are decreased.  
Efforts should be made to particularly target men who were found to be accessing ARVs at an 
unusually low rate compared to women in this study. Men should therefore be targeted specifically to 
encourage increased health seeking behaviour so that they would increasingly access the VCT and 
HAART programmes in the health care facilities as well. This can be done through mass mobilisation 
programmes on community radio stations to encourage men to interact more with the health care system 
starting with going for voluntary counselling and testing, disclosing to their partners (those on HAART), 
training as “treatment buddies” and volunteering as peer counsellors or adherence counsellors to fellow 
men within the health care facilities. Studies targeting men to evaluate their level of access to VCT should 
be done and reasons why very few of the men access such services addressed within the study. Other 
studies can be done to identify the factors that facilitate the high uptake of women onto HAART 
programmes in order to sustain the current trend. 
Regarding health care providers and their relationship with the patients, more understanding of 
the patient should be encouraged especially by building a rapport with the patient in order to remove the 
feeling that the health care workers are judgemental of their patients especially when non adherent. Finally 
increased support for training and further research about adherence and antiretroviral medication to 
address the side effects and regimen complexity should be done if challenges to adherence are to be 
addressed. This will then help understand the problem of patients skipping medications because patients 
are either travelling out of town or skipping medication due to side effects. 
Introduce and ensure that simple methods to measure adherence are monitored and evaluated 
periodically to keep track of the trends in adherence within the population being served by the public 
health sector HAART programmes. Pharmacy refill records, doctors’ assessments as well as standardised 
one month recall should be used in addition to the usual clinical criteria of physiological markers like CD4 
counts and plasma viral loads. More needs to be done to enhance and strengthen the treatment buddy 
programme in terms of research and helping set up of more programmes especially in Impilisweni where 
the author found them to be under utilised. This could be done hand in hand with the introduction of 
peer support groups at the health care centre to help the patients deal with the reality of HAART and gain 
coping strategies and emotional support from each other while on treatment. This should ultimately lead 
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to improved levels of adherence in the long term as the patients become more activated and empowered 
to deal with long term HAART. 
At the health system level, the National Department Of Health, SA should consider enacting 
inclusive policies that give lifelong social grant support for people who are on HAART especially those in 
public sector. Both patients with a CD4 count of above and below 200 should be eligible or better still 
eligibility should not depend on CD count as a measure since one stays sick even if their CD4 count is 
high. Perhaps applying equitable scales to determine the poorest of the poor may help in this regard. This 
money then helps to reduce drug treatment holidays as patients skip medications on certain days due to 
various reasons since they are too poor to afford food which is essential for proper adherence. The 
government should ensure/consider increasing social support and welfare for PLWHA on HAART by 
increasing access to disability grant services to cater for transport and problems associated with lack of 
food and telecommunication (money for sms ,cell phone airtime  and telephone calling cards). 
Finally increased support for training and further research about adherence and antiretroviral 
medication to address the side effects and regimen complexity should be done if challenges to adherence 
are to be addressed. This will then help understand the problem of patients skipping medications because 
patients are either travelling out of town or skipping medication due to side effects. 
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E. ARV ADHERENCE QUESTIONNAIRE 
 
CONSENT 
 
INTERVIEWER INTRODUCES HIM/HERSELF, AND THE STUDY, AND THEN…. 
I would like to ask you questions to ensure that the information I have provided so far is clear, and give you 
the opportunity ask any question(s) you have.  
 
NO QUESTION RESPONSE CODES 
1.  Do you understand the purpose of the study, and what will 
be required of you if you agree to take part? 
 Yes=1 
No=0 
2.  If no, what further questions what further questions do you 
wish? 
 
3.  Do you understand that any time you may withdraw from 
this study without giving a reason? 
 
4.  Do you understand that this study is in no way linked to the 
organizations that provide care, and withdrawing or 
participating will not affect the care that you receive? 
 
5.  Do you agree to take part in this study?  
Written consent 
I agree to participate in this study, having understood and answered yes to all of the above questions. 
Initials of respondent: …………………………………………………………………….. 
Verbal consent 
As the respondent is illiterate, or is happy to provide verbal but not written consent, I, the field worker, confirm that 
the respondent gave verbal consent to be interviewed. 
Signature of interviewer:  ……………………………………………………………………. 
INTERVIEW DETAILS 
 
NO QUESTION RESPONSE CODES SKIP 
6.  Clinic patient number (8 digits + 2 letters) 
  
7.  
Facility name  Carltonville = 1 
Zola = 2 
Empilisweni = 3 
Natalspruit = 4 
 
8.  Date of interview  
D D M M Y Y Y Y   
9.  
Name of interviewer  Interviewer 
names =1 
=2  
=3 
=4 
 
Signature of researcher that has 
checked questionnaire 
 
   
 64 
 
10.  Questionnaire number 
ONLY TO BE COMPLETED ONCE 
QUESTIONNAIRE HAS BEEN CHECKED, AND IS 
COMPLETE 
    
 
SECTION 1: SOCIO-DEMOGRAPHIC BACKGROUND 
 
I would like to ask you a few questions about yourself. We are asking these questions of everybody 
participating in this study. Feel free to stop me if you have any questions.
No. QUESTIONS  RESPONSES CODES SKIP 
11.  GENDER  Male 
=01; 
Female=
02 
 
12.  What is your date of birth? 
WRITE AGE IF DATE NOT KNOWN 
D D M M Y Y Y Y   
13.  What is the highest educational level that you 
have COMPLETED? 
 
 No formal education 
=0 
Grade 1/SubA=1 
Grade 2/Sub B=2 
Grade 3/Standard 1 =3 
Grade 4/Standard 
2/ABET L1 =4 
Grade 5/Standard 3=5 
Grade 6/Standard 
4/ABET L2=6 
Grade 7/Standard 5 =7 
Grade 8/Standard 
6/ABET L3 = 8 
Grade 9/Standard 7 = 9 
Grade 10/Standard 
8/ABET L4 = 10 
Grade 11/Standard 9 = 
11 
Grade 12/Standard 
10/ABET L5 = 12 
Diploma = 13 
Degree = 14 
Other: Specify--------
=99 
 
 
14.  Have you done any activity to earn money in the past two weeks? IF NO, 
>Q17 
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15.  IF YES: Can you describe the type of work you have been doing, including how often 
you do this work? 
PLEASE WRITE EXPLANATION 
 
 
 
 
16.  IF WORKING: How would you best describe the 
work that you do? 
 Full time =1 
Self-employed = 2 
Casual or part-time 
work  = 3 
 
17.  Do you currently receive a disability grant?  Yes=1 
No=0 
IF YES 
>Q19 
18.  IF NO:  Have you applied for one?  Yes=1 
No=0 
 
 
I’d like to now ask you about your costs coming here today  
 ITEM COST 
PER 
VISIT 
Codes 
19.  How much did it cost you to travel to and from the 
hospital/clinic (the return trip)? 
R Don’t know = -1 
 
PUT ZERO IF 
SPENT NO MONEY 
ON ITEM 
 
20.  Subsistence (food) during visit? R 
21.  Medication received at hospital/clinic? R 
22.  Consultation at hospital/clinic? R 
23.  Accommodation (if needed to stay over) during visit? R 
24.  Are there any other COSTS that I have not 
mentioned? 
 Yes =1 
No = 0 
25.  IF YES: What else did you spend money on, and how much? 
26.  At present, do you have a medical aid?   Yes =1 
No=0 
 
27.  DID THE PERSON SAY THEY HAVE BEEN 
WORKING IN THE PAST TWO WEEKS? CHECK Q15 
 Yes =1 
No = 0 
IF NO, 
> Q31 
28.  IF YES, Did you miss work by coming here?   Yes =1 
No = 0 
IF NO, 
> Q31 
29.  IF YES: Did you loose salary or income by coming 
here? 
 Yes =1 
No = 0 
IF NO, 
> Q31 
30.  IF YES, How much income do you lose per visit? 
    
 
R____________per visit 
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31.  What is the main source of drinking water for 
members of your household? 
READ OUT EACH OPTION 
 
Other: Specify…………………………………………… 
 
 
 Rain water /tank = 1 
Borehole/well = 2 
Water carrier/tanker 
= 3 
Public tap = 4 
Piped water (tap) in 
site, yard = 5 
Piped water (tap) in 
dwelling = 6 
Bottled water = 7 
Other = 99 
 
32.  What kind of toilet facility does your household have? 
READ OUT EACH OPTION 
 
Other: Specify…………………………………………. 
 
 Flush toilet (own)=5 
Flush toilet (shared) 
= 4 
Bucket latrine = 3 
Pit latrine=2 
No facility/bush or 
veld = 1 
Other=99 
 
 
33.  What type of home do you live in? 
READ OUT EACH OPTION 
 
Other: 
Specify…………………………………………. 
 
 Shack / informal dwelling in 
back yard=1 
Shack / informal dwelling =2 
Hostel =3 
House/flat/Room in back 
yard=4 
Room/flatlet not in back yard 
but on shared property=5 
Flat in a block of flats = 6 
Formal house = 7 
Other = 99 
 
34.  What is the main material of your house’s 
floor? 
READ OUT EACH OPTION 
 
 
Other: 
Specify…………………………………………. 
 
 Earth / sand / dung = 1 
Bare wood planks = 2 
Cement = 3 
Vinyl or plastic = 4 
Carpet/ tiles/ polished wood = 
5 
Other = 99 
 
35.  What is the main material of your house’s 
wall? 
READ OUT EACH OPTION 
 
Other: 
Specify…………………………………………. 
 
 Plastic / cardboard = 1 
Mud = 2 
Mud and cement = 3 
Corrugated iron / zinc = 4 
Bare brick / cement blocks = 
5 
Plaster / finished = 7 
Other = 99 
 
36.  Do you have electricity in your household?   Yes=1 
No = 0 
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Can you tell me if you household has any of the following appliances, that are working?  
37.  Television  Yes=1 
No = 0 38.  Telephone (land line)  
39.  Fridge  
40.  Personal computer  
41.  Washing machine  
42.  Radio  
43.  Cell-phone  
44.  What does your household use mainly for 
cooking? 
READ OUT EACH OPTION 
 
If other, specify……………………………… 
 Electricity =6 
Gas = 5 
Paraffin = 4 
Wood = 3 
Coal = 2 
Animal 
dung=1 
Other = 99 
 
45.  What does your household use mainly for 
heating? 
READ OUT EACH OPTION 
 
If other, specify……………………………… 
 Electricity =6 
Gas = 5 
Paraffin = 4 
Wood = 3 
Coal = 2 
Animal 
dung=1 
Nothing=7 
Other = 99 
 
46.  What does your household use mainly for 
lighting? 
READ OUT EACH OPTION 
 
If other, specify……………………………… 
 Electricity =6 
Gas = 5 
Paraffin = 4 
Wood = 3 
Coal = 2 
Animal 
dung=1 
Other = 99 
 
Does any member of your household own any of the following?  
47.  A bicycle  Yes=1 
No = 0 
 
48.  A motorbike  
49.  A car  
50.  A donkey or horse  
51.  Sheep or cattle  
52.  Would you say that the people at home often, 
sometimes, seldom or never go hungry? 
 Often = 
1 
Someti
mes = 2 
Seldom 
= 3 
Never 
= 4 
 
53.  Do you receive food supplement/food parcel from any source?   Yes = 
1, No 
=0 
 
 
SECTION 2: KNOWLEDGE OF HIV/AIDS AND ARVs 
 
I would now like to ask you some questions about AIDS and ARVS 
NO QUESTION RESPONSE CODES SKIP 
54.  Can you tell me about ARVs, what do they do?  
WRITE RESPONSE 
 
 
 Correct 
response=1 
Incorrect 
response =0 
Don’t know 
= -1 
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I am going to read you some statements. I would like you to tell me, for each one, whether you 
think the statement is True or False, or you don’t know 
 
55.  People receiving ARVs can still transmit HIV to other 
people through unprotected sex. 
 True = 1 
False = 0 
Don’t know 
= -1 
56.  It is acceptable to stop ARVs after gaining weight  
57.  It is acceptable to stop ARVs when one no longer 
suffers from opportunistic infections 
 
58.  ARVs cure HIV/AIDS.  
59.  After a couple of years one can stop taking ARVs.  
60.  Missing a few tablets of ARVs is acceptable.  
61.  Unprotected sex is safe when one is taking ARVs  
SECTION 3: CONTINUITY OF CARE 
 
I will like to obtain some information from you about when you were diagnosed with HIV or AIDS and 
where and how you have received treatment and care. 
NO QUESTION RESPONSE COD
ES 
SKIP 
62.  When did you first test positive for HIV?  
 
D D M M Y Y Y Y Don’
t 
know 
= -1 
 
At which health care facility (clinic or hospital) did you FIRST test HIV positive?    
63.   
Name of clinic or hospital:………………………………………. 
 
64.  FILL IN IF YOU KNOW 
Town / City:……………………………………….. 
 
65.   
Province:  
 Gauteng = 1 
Mpumalanga = 2  
Limpopo = 3 
North West = 4 
Free state = 5 
E. Cape = 6 
W. Cape 
= 7 
N. Cape 
= 8 
KZN=9 
Where did you FIRST seek treatment after you were FIRST diagnosed with AIDS?  
66.   
Name of clinic or hospital:………………………………………. 
 
67.   
Town / City:……………………………………….. 
 
68.   
Province:  
 Gauteng = 1 
Mpumalanga = 
2  
Limpopo = 3 
North West = 4 
Free state = 5 
E. Cape = 6 
W. Cape 
= 7 
N. Cape 
= 8 
KZN=9 
69.  When did you FIRST begin taking 
ARVs?  
 
D D M M Y Y Y Y Don’t 
know = -
1 
 
70.  Have you received ARVs from a 
clinic / service other than this one?  
 Yes = 1; 
No = 0 
IF NO, >Q74 
Can you tell me the name of the clinic / hospital, which town/city AND province?  
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71.   
Facility name:……………………………………………… 
 
72.   
Town / city: ………………………………………………. 
 
73.   
Province 
 Gauteng = 1 
Mpumalanga = 2  
Limpopo = 3 
North West = 4 
Free state = 5 
E. Cape = 6 
W. Cape = 7 
N. Cape = 8 
KZN=9 
 
 
SECTION 4: ADHERENCE 
 
I would like to ask you some questions about how you are coping with taking the ARVs regularly. We want 
to understand better the real life challenges that people on ARVs face in taking their pills. 
 
NO QUESTION RESPONSE CODES SKIP 
74.  Can you tell me the name of each of your drugs?  
(WITHOUT LOOKING AT THE CONTAINER)  
 
 Yes = 1 
No = 0 
IF YES 
>Q76 
75.  IF NO: Can you point to the pictures of each of 
your drugs?  
OR PERSON READS THE NAMES FROM THE 
CONTAINERS 
 
WRITE IN ALL DRUG NAMES BELOW FIRST 
AND THEN GO BACK ASK QUESTIONS ABOUT 
EACH ONE? 
 Yes = 1 
No = 0 
 
76.  DRUG 1: WRITE DRUG NAME GIVEN, CHECK SPELLING ON LIST 
 
 
 
77.  How many times a day to do you take ……. (drug)?   
78.  How many tablets of …… (drug) do you take in one day?   
79.  DRUG 2: WRITE NAME GIVEN, CHECK SPELLING ON LIST 
 
 
 
80.  How many times a day to do you take …… (drug)?   
81.  How many tablets of ……. (drug) do you take in one day?   
82.  DRUG 3; WRITE NAME GIVEN, CHECK SPELLING ON LIST 
 
 
 
83.  How many times a day to do you take ….. (drug)?   
84.  How many tablets of ….. (drug) do you take in one day?   
85.  DRUG 4: WRITE NAME GIVEN, CHECK SPELLING ON LIST 
 
 
 
86.  How many times a day to do you take …… (drug)?   
87.  How many tablets of …. (drug) do you take in one day?   
People may miss taking their ARVs for various reasons. What, in your experience, are the main reasons why 
people miss their tablets? WRITE RESPONSES, PROMPT FOR MORE THAN ONE REASON  
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88.  Reason 1:  
 
 
  
89.  Reason 2: 
 
 
 
90.  Reason 3 
 
 
 
For each of drugs, can you tell me how many tablets, if any, you missed YESTERDAY?    
WRITE IN DRUG NAMES FROM ABOVE 
 
 NAME OF DRUG Number of 
tablets missed 
Reason for missing  
91.  Drug 1    
92.  Drug 2    
93.  Drug 3    
94.  Drug 4    
For each drug, can you tell me how many tablets, if any, you missed THE DAY BEFORE 
YESTERDAY (INDICATE WHICH DAY YOU ARE REFERRING TO - MON, TUE ETC.)?   
WRITE IN DRUG NAMES  
 NAME OF DRUG Number of 
tablets missed 
Reason for 
missing 
  
95.  Drug 1    
96.  Drug 2    
97.  Drug 3    
98.  Drug 4    
For each drug, can you tell me how many tablets, if any, you missed 3 DAYS AGO?   
(INDICATE WHICH DAY YOU ARE REFERRING TO - MON, TUE ETC.)?   WRITE IN 
DRUG NAMES  
 NAME OF DRUG Number of 
tablets 
missed 
Reason for missing   
99.  Drug 1    
100.  Drug 2    
101.  Drug 3    
102.  Drug 4    
103.  If you didn’t miss any tablets in the 
last three days, when was the last 
time you missed any of your 
medications? 
 Within the last:  
Week =1 
2 weeks = 2 
3 months = 3 
More than 3 
months ago = 4 
Never missed = 
5 
104.  IF EVER MISSED TABLETS: 
What is the longest time you have ever missed 
your tablets? 
 INDICATE 
DAYS OR 
MONTHS 
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105.  Do you belong to a support group?  Yes=1,  
No= 0 
If NO,  
>Q115 
106.  IF YES: How often do you attend?  Weekly = 1 
Monthly = 2 
Occasionally 
=3 
 
IF YES, What services are offered at the support group? 
READ OUT EACH OPTION 
 
107.  Advice and information on staying healthy e.g. nutrition, 
exercise and prevention 
 Yes=1,  
No= 0 
108.  ARV information: CD4 counts, ARVs, viral load  
109.  Treatment buddies  
110.  Help with collecting medicines from the clinic  
111.  Home visits  
112.  Food  
113.  Income generating activities  
114.  Individual counselling and emotional support    
Do you receive any of the following help or support from your friends or family to help you take your tablets 
regularly? 
READ OUT EACH OPTION 
115.  They visit you  Yes=1,  
No= 0 
 
116.  They send an sms or call you by phone  
117.  They give you food to take your pills with  
118.  They provide transport money to the clinic  
119.  They provide emotional support  
120.  Is there any other type of help that you receive? 
 
Specify:………………………………………… 
 
121.  Are there people interested in buying ARVs?  Yes =1, 
No=0 
Don’t 
know = -
1 
 
122.  Do you know of people who have sold their ARVs?   
123.  Has there ever been a month when you couldn’t come to clinic 
for your monthly visit? 
 Yes =1 
No=0 
IF NO >135 
124.  IF YES, how many times did you miss coming in the last 6 
months, since _____ (MONTH)? 
   
IF YES, What was the reason for skipping the appointment?  
READ OUT EACH OPTION 
 
125.  You were working  Yes =1 
No=0 
Not 
relevant - 
2 
 
126.  You were sick  
127.  You forgot  
128.  You mixed up the dates  
129.  You were away out of town  
130.  You had no transport money  
131.  You had nobody to look after the children  
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132.  You were afraid that somebody would see you and judge you 
negatively 
 
133.  You were afraid that your partner would find out and ask me 
to explain 
 
134.  Is there any other reason that made you miss your visit? 
 
Specify reason:………………………………………….. 
 
135.  Can you tell me in your own words what a CD4 count is? 
WRITE DOWN WORDS HERE: 
 
 
 
 
136.  Can you tell me what your most recent CD4 count is?  Write in 
number 
given, 
OR, 
Don’t 
know = -
1 
 
137.  When are you due for your next CD4 count?  MONTH 
AND 
YEAR 
 
SECTION 5: QUALITY OF CARE/PATIENT PROVIDER RELATIONSHIP 
I would now like to know about your experiences when at this clinic and how the health providers interact 
with you. 
138.  Are you able to talk to the health workers in private?   Yes = 1, 
No = 0 
If YES 
>Q140 
139.  IF NO, does it bother you?    Yes =1, 
No=0 
 
140.  How many hours do you spend at the clinic at each visit?  INDICA
TE 
HOURS 
 
I am going to read some statements about your meeting with the health workers today. Can you tell me 
whether you agree or disagree with these statements? 
IF THE PERSON CAN’T DECIDE CHOOSE NO VIEW/DON’T KNOW
141.  The queues to be seen by a doctor or nurse are too long at 
this facility 
 Agree=1 
Disagree=2 
Agree and 
disagree=3 
No 
view/don’t 
know=4 
Not 
relevant= -
2 
 
142.  The health worker DID’NT discuss the treatment fully 
with you, including how the treatment works and side 
effects.  
 
143.  It is a problem that the health worker DOESN’T speak 
your language 
 
144.  You find it difficult to tell the health worker when you 
have missed taking your tablets 
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145.  You would not tell him/her because s/he would shout at 
you. 
 
 
 
 
 
146.  The health worker was too busy to listen to your problems   
147.  The health worker provided you with feedback on whether 
the drugs were working or not 
 
148.  The health worker understood the difficulty of taking the 
drugs and assisted you where possible 
 
149.  Some staff DO NOT treat patients with sufficient respect.   
150.  When I need to obtain other care that they cannot provide 
in this clinic, I was given enough help to get to the right 
place 
 
151.  The health workers I see care about me.  
152.  Since enrolling at this clinic/hospital, have you ever left 
without being helped  
 
 
Yes=1 
No=0 
IF NO >Q154 
153.  IF YES, why did you leave without being helped? 
WRITE FULL EXPLANATION:  
 
SECTION 6: SOCIAL SUPPORT AND ACCEPTANCE 
 
I would like you to tell me about the support your receive to help you cope with your HIV status and to take 
your ARVs. 
154.  Apart from the health workers, have you told anyone 
about your HIV status? 
 Yes =1 
No= 0 
If NO,  
> Q162 
IF YES, whom of the following have you told about your HIV status?  READ OUT EACH 
OPTION 
 
 
155.  Spouse / partner, if you have one  Yes =1 
No= 0 
If no spouse = -2 
Yes = 1, No = 0 
Don’t know =-1 
156.  Family member  
157.  Friend  
158.  Neighbour  
159.  Religious leader   
160.  No-one  
161.  Is there another category of person to whom you have 
told your status we have not already mentioned?  
Other (specify)------------------ 
 
162.  Has your HIV status been disclosed to other people 
without your permission? 
 
 
Yes=1 
No=0 
Do you keep your status secret for any of the following reasons:  
READ OUT EACH OPTION 
163.  Fear of rejection by family  Yes =1 
No= 0 
 
 
164.  Fear of rejection by friends  
165.  Fear of violence  
166.  I do not trust people   
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167.  I will not get help from others if they know my status  
168.  Fear that I will be stigmatised   
169.  Fear that people will gossip about me  
170.  Fear that HIV my status will be known by the 
community 
 
171.  Fear that my partner will know and ask me to explain  
172.  Is there any other reason? 
 
Specify …………………………………………… 
 
I would like to ask you how supportive your family, friends and colleagues are towards you.  
173.  How would you describe your partner’s behaviour 
towards you, if you have a partner – supportive or 
unsupportive? 
 Supportive=1  
Unsupportive=2 
Both supportive and 
unsupportive=3 
Not relevant=4 
 
174.  How would you describe the behaviour of your family 
towards you? 
 
175.  How would you describe the behaviour of your friends 
towards you? 
 
176.  How would you describe the behaviour of the people you 
live with towards you? 
 
177.  How would describe the behaviour of your work 
colleagues towards you? 
 
  
  
SECTION 7: FOLLOW-UP  
We are planning to do a more detailed study, visiting a few 
patients in their homes to find out more about how they are 
coping the HIV and the treatment. Would you be willing to be 
part of that study?  
IF YES, WRITE NAME AND TEL NO ON SEPARATE PIECE OF 
PAPER 
 Yes=1 
No = 0 
 
 
THAT IS THE END OF THE INTERVIEW DO YOU HAVE ANY QUESTIONS YOU 
WANT TO ASK ME?............................................................................................................... 
 
DO YOU WANT TO ADD ANYTHING? WRITE IN SPACE BELOW OR ON BACK OF 
QUESTIONNAIRE…………………………………………………………………………… 
 
MANY THANKS FOR YOUR HELP – WE REALLY APPRECIATE IT! 
 
 
INTEVIEWER: PLEASE COMPLETE THESE QUESTIONS IMMEDIATELY AFTER THE 
INTERVIEW. 
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178.  INTERVIEWER: How clear was the meaning of the 
respondent’s answers 
 Good = 1 
Average =2 
Poor = 3 
 
179.  INTERVIEWER: How attentive was the respondent to 
the questions during the interview? 
 Good = 1 
Average =2 
Poor = 3 
 
180.  INTERVIEWER: What was your impression about this 
person’s willingness to talk in more detail about their 
illness and how they are coping with it? 
 Willing = 1 
Doubtful = 2 
Unwilling = 
3 
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F. RECORDS REVIEW SHEET  
Patient Adherence to ARV Treatment in Four Sites in Gauteng 
RESPONDENT DATA CAPTURE SHEET 
Name: Hospital/ Clinic: …………………………………………..  
Client file Number 
Date (Day/Month/Year)  
D D M M Y Y 
FILE RECORD  
Type of Data  Information Required  
Start date for ART treatment   
Date stopped treatment (If applicable)   
Total visits scheduled  
(April 2005 and March 2006)   
Actual Number of visits made during this period   
Last viral load count  
Date of current 
test  CD4 count  Next scheduled test  
   
Last CD4 cell count  
Date of current 
test  CD4 count  Next scheduled test  
   
Screening for TB  
Dale of screening  Result: Neg/Pos  Treated for TB (Yes No) 
   
 
      
